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ABSTRACT 
Scientists have considered glia as mere passive allies of neurons for a long time. As a 
consequence, their functions have been greatly underestimated. Major discoveries made in 
the last three decades have changed our view on glial cells and it is now accepted that they 
play important roles in health and disease. In this thesis, we have investigated the role of 3 
glial cell types - astrocytes, microglia and ependymal cells - in spinal cord injury (SCI), 
rheumatoid arthritis (RA) and in pain-related processes.   
 
In Study I, we have delineated the mechanisms that regulate interleukin-6 (IL-6) 
expression and secretion in adult rat astrocyte cultures. We found that the PI3K-mTOR-
AKT pathway negatively regulates IL-6 expression and that IL-6 secretion is calcium 
(Ca2+)-dependent. Interestingly, we observed that astrocytes express IL-6 in vivo after SCI, 
however IL-6 levels decline after 2-3 weeks. Since induction of IL-6 in reactive astrocytes 
could be beneficial due to the regenerative properties of this cytokine, we treated adult rats 
2 weeks after SCI with mTOR inhibitors, torin2 and rapamycin, to boost astrocytic IL-6 
secretion by blocking the PI3K-mTOR-AKT pathway and increasing cytosolic Ca2+, 
respectively. This combinatorial treatment led to a transient improvement in mechanical 
hypersensitivity during the treatment period.   
 
In Study II, we have established an adult ex vivo model of SCI, to facilitate the study of 
cellular processes that are difficult to address using animal models. In particular, we 
focused on assessing the ependymal cell response to injury in our model, which is based on 
adult mouse spinal cord cultured tissue slices. Interestingly, we found that, ependymal cells 
become activated, proliferate, migrate out of the ependymal layer and differentiate in a 
manner that fundamentally resembles their response to injury in vivo. Moreover, we show 
that these cells can respond to external adenosine triphosphate (ATP) stimulation and that 
some of them have spontaneous Ca2+ activity. We believe that this model is a useful 
platform to study and modulate ependymal cell responses and could contribute to the 
development of novel treatment avenues for SCI.  
 
In Study III, we have investigated mechanisms that may participate in central sensitization 
in the context of RA. Here, we report for the first time the presence of disease associated 
autoantibodies known as ACPA (anti-citrullinated protein antibodies) in the cerebrospinal 
fluid (CSF) of a subset of RA patients. Moreover, we show that intrathecal injection of such 
antibodies into the CSF of mice led to pain-like behavior, while injection of other 
antibodies from RA patients or from healthy individuals did not. Furthermore, we show that 
co-stimulation of human astrocytes in culture with ACPA and interleukin-1beta (IL-1ß) led 
to IL-6 secretion in these cells, an effect that was blocked upon addition of an Fc-gamma 
receptor 1 (FcγRI) inhibitor. These findings support the notion that ACPA may enter the 
central nervous system (CNS) of RA patients, act on glial cells and activate pathways that 
could contribute to centrally mediated pain.   
 
In Study IV, we have investigated differences between male and female spinal microglia in 
the context of arthritis-induced persistent pain. We focused on the late phase of the collagen 
type-II antibody induced arthritis (CAIA) animal model, which occurs after joint 
inflammation has resolved and it is characterized by persistent mechanical hypersensitivity 
and spinal glial activation. We found that intrathecal delivery of minocycline, often 
described as a microglial inhibitor, was able to revert CAIA-induced pain in male, but not 
female mice. Moreover, using flow cytometry we found that females had lower dorsal horn 
spinal microglial relative numbers as compared to males. Furthermore, genome-wide RNA 
sequencing results pointed to several transcriptional differences between male and female 
microglia, while no convincing differences were identified between control and CAIA 
groups. Taken together, these results suggest that during the late phase of the CAIA model 
changes in microglial gene expression might be highly localized or short-lasting, and that 
the sexually dimorphic response to minocycline might additionally involve other factors 
such as changes in protein expression or epigenetic modifications. 
 
In summary, this thesis expands our understanding of mechanisms that are important in 
glial cell responses to pathological events and opens new avenues to explore the modulation 
of glial cells. The ultimate hope is that continued efforts will result in the discovery of 
suitable targets for therapy in individuals with spinal cord injury, rheumatoid arthritis and 
chronic pain.   
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1 INTRODUCTION 
The story of glia is often considered to have officially started in 1856, when the German 
scientist Rudolf Virchow identified a connective tissue surrounding nerve elements which 
he termed neuroglia (from the Greek nerve glue) [1]. During the second part of the 19th 
century, the concept of glial cells started to gain ground, as a result of the discoveries made 
by Otto Deiters, Camillo Golgi and Gustav Retzius among others [2-4]. Michael von 
Lenhossek coined the term astrocyte in 1893, whereas the recognition of microglia and 
oligodendrocytes as distinct glial cell types came in 1919-1921 by the hand of Pío del Río-
Hortega, a disciple of Santiago Ramón y Cajal [5, 6].  
 
Initially, neuroglia was considered to be an inert element, a mere “filling” for the area void 
of neurons. This concept soon evolved to the idea that glia could serve as a structural 
support for neurons. Later on, Golgi and Cajal postulated that neuroglia could also provide 
nutritional support and insulation to neurons. The overall conviction was that glia were a 
passive ally of the neuron: the one-and-only central and active cell type of the central 
nervous system (CNS). Nevertheless, it was apparent already then, that these non-neuronal 
cells were highly heterogeneous, and could undergo changes in pathological conditions [7]. 
Major discoveries made in the 20th century have changed our view about glial cells. The 
past few decades have experienced a rise in glial research, owing to the discovery that glial 
cells can be excited, albeit in fundamentally different ways than neurons [8]. Moreover, it is 
now well-accepted that glial cells have important active roles in health and disease [9].  
 
In this thesis, we have investigated the role of astrocytes, microglia and ependymal cells in 
pathological conditions. Therefore, the scope of this dissertation will be focused on the 
involvement of these three glial cell types in spinal cord injury (SCI), rheumatoid arthritis 
(RA) or pain-related processes. 
1.1 GLIAL CELLS 
1.1.1 Astrocytes 
Astrocytes are one of the most abundant cell types in the CNS. These cells are highly 
heterogeneous and their morphology, function and response to injury mainly varies 
depending on their developmental stage, anatomical location, gene expression profile and 
physiological properties [10]. Astrocytes have been classically characterized into two main 
subtypes. Protoplasmic astrocytes are confined to the grey matter and have a bush-like 
shape, with thick stem branches and numerous fine processes (Figure 2). Fibrous astrocytes 
are distributed along white matter tracks and have a fiber-like appearance with fewer 
branching processes. Both subtypes are in contact with blood vessels however, while the 
processes of protoplasmic astrocytes surround synapses, fibrous astrocytes contact Nodes of 
Ranvier [11].  
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Astrocytes are organized in non-overlapping domains, where only the fine processes of 
neighboring astrocytes interdigitate and form gap junctions, creating a highly dynamic 
astrocyte network [12]. Astrocytes are not electrically excitable and instead rely on calcium 
(Ca2+) signals for communication [13]. Astrocytes can increase intracellular Ca2+ both in 
localized regions of their fine processes and in their soma [14]. Such cytosolic Ca2+ 
elevations can occur in response to external stimuli such as neurotransmitters and by Ca2+ 
release from intracellular stores [12]. Notably, Ca2+ signals can be oscillatory and confined 
to a single astrocyte or they can propagate from one astrocyte to another as a Ca2+ wave by 
diffusion of inositol 1,4,5-trisphosphate (IP3) through gap junctions and by extracellular 
release of adenosine triphosphate (ATP) [15]. Astrocytic Ca2+ signalling plays an important 
role in signal transduction, for example by regulating the release of gliotransmitters and 
cytokines [16, 17].  
 
The wide heterogeneity of astrocytes makes it challenging to find a unique and specific 
marker that can label them all. Glial fibrillary acidic protein (GFAP) has been used as the 
prototypic astrocyte marker for over 30 years [18]. Nevertheless, it is now clear that GFAP 
is not expressed by all astrocytes and that other cells in the CNS can express GFAP (see 
Study II). The most promising marker for astrocytes is perhaps aldehyde dehydrogenase 1 
family member L1 (ALDH1L1), which was elucidated by transcriptomic analysis, 
revealing that it is highly, broadly and specifically expressed in astrocytes [19]. 
 
Figure 1 Astrocytes form functional barriers (glia limitans) that separate neural from non-neural tissue along the 
vasculature (a) and the meninges (b). Astrocyte scars, which are fundamentally similar to the glia limitans, separate CNS 
lesions from the healthy parenchyma (c). The glia limitans works in concert with other functional barriers such as the 
brain or spinal-cord blood barrier to restrict the entrance of leukocytes into the CNS parenchyma. PBM = parenchymal 
basement membrane; EBM = endothelial basement membrane; SAS = subarachnoid space. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Neuroscience, Sofroniew, M.V. Astrocyte barriers to neurotoxic inflammation 
© (2015) 
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Astrocytes play important roles in the formation, maintenance and pruning of synapses thus 
controlling the connectivity of neuronal circuits [9]. Moreover, it has been proposed that 
astrocytes can directly influence and regulate synaptic transmission [20]. Furthermore, 
astrocytes provide essential metabolic support to neurons, regulate blood flow and maintain 
extracellular homeostasis [11]. Astrocytes also form barriers known as glia limitans that 
separate neural from non-neural tissue along perivascular spaces and the meninges. The 
glia limitans works in concert with other functional barriers, such as the blood-spinal 
cord/brain barrier to restrict CNS inflammation (Figure 1) [21]. 
1.1.2 Ependymal cells 
Ependymal cells are mostly known as the glial cell type that lines the central canal of the 
spinal cord and the brain ventricles (Figure 2). These cells circulate cerebrospinal fluid 
(CSF) and regulate the bi-directional transport of molecules between the CSF and CNS 
parenchyma [22, 23]. Ependymal cells are heterogeneous, and have been broadly divided 
into three types. Cuboidal ependymal cells are multi-ciliated and are considered the most 
abundant cell subtype. Tanycytes have one luminal cilium and one basal process that can 
contact blood vessels. Radial ependymal cells are far less numerous and are found in the 
dorsal and ventral poles of the central canal lining, where they extend long processes along 
the dorso-ventral axis [24, 25].  
 
Ependymal cells express markers characteristic of neural stem cells and precursors such as 
Vimentin, Nestin, Sox2, Sox9 and CD133/prominin-1 [24, 26, 27]. Some of these markers 
are expressed throughout the ependymal layer, while others are restricted to certain 
ependymal subpopulations (see for example Study II). In the intact spinal cord, adult 
ependymal cells are mostly quiescent, occasionally self-renewing to maintain their numbers 
[28, 29]. This proliferation is not spread evenly distributed, and it mostly occurs in 
ependymal cells of the dorsal region of the central canal in close proximity to blood vessels 
[26]. Lineage tracing experiments have demonstrated that ependymal cells hold neural stem 
potential, as these cells can from neurospheres across multiple cell passages and can 
differentiate into astrocytes, oligodendrocytes and neurons in vitro [24, 30]. This has 
prompted a vast interest on the study of these cells for regenerative therapies.  
 
Like in astrocytes, Ca2+ signalling appears to play an important, albeit understudied role in 
ependymal cells. For instance, Ca2+ signalling regulates ciliary beating of brain ependymal 
cells, which is essential for circulating CSF [31]. Moreover, brain ependymal cells can 
respond to ATP via P2X7 purinergic receptors (P2X7R), leading to an increase in 
intracellular Ca2+ levels [32, 33]. The exact role that Ca2+signaling plays in spinal cord 
ependymal cells remains unknown. Nevertheless, these cells possess gap junctions [34-36] 
which can potentially enable ependymal-ependymal or even ependymal-astrocyte 
communication.  
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1.1.3 Microglia 
Microglia are the predominant resident immune cells of the CNS (Figure 2). In mice, they 
originate from primitive myeloid in the yolk-sac and invade the CNS during early 
embryonic development, proliferating and spreading ubiquitously across the parenchyma 
thereafter [37, 38]. Although this cell population was thought to be long-lived [39], new 
evidence has shown that microglia have a high turnover rate in both rodents and humans, 
allowing a complete self-renewal of their whole population one to several times across a 
lifetime [40-42]. Under physiological conditions, microglia exhibit a ramified morphology, 
with a small soma and multiple fine processes that survey the CNS parenchyma about every 
hour [43]. Like astrocytes, each microglial cell has its own territory, and microglial 
processes rarely overlap with each other [44]. Microglia have the ability to phagocytose, 
which is essential for clearing debris [45] and for synaptic pruning during development and 
the postnatal period [46, 47]. Moreover, they can also monitor neuronal activity and 
synaptic plasticity [48, 49] and regulate adult neurogenesis [50]. Several studies examining 
microglial expression profiles have reported that microglia display heterogeneity among 
several brain regions [51, 52]. Furthermore, microglial sex differences under physiological 
conditions have also been described. Of note, microglial density varies among males and 
females during development and adulthood, in areas such as the amygdala, hippocampus 
and parietal cortex [53, 54]. 
1.2 GLIOSIS 
Glial cells can become “activated” or “reactive” in response to changes induced by trauma 
or pathological events [55, 56]. A large repertoire of molecules which can be released by 
different cell types can elicit or regulate diverse aspects of gliosis. Some of these include 
cytokines and growth factors such as interleukin-6 (IL-6), tumor necrosis factor-alpha 
(TNF-⍺) or fibroblast growth factor 2 (FGF2), neurotransmitters (norepinephrine, 
glutamate), purines (ATP) and reactive oxygen species (ROS) [11]. In this section, general 
characteristics of astrogliosis and microgliosis are described (relevant for Study I, Study 
III and Study IV), while SCI induced responses in astrocytes and ependymal cells 
(relevant for Study I and Study II) will be discussed in more detail further below. 
Figure 2 A) Transgenic hGFAP-GFP protoplasmic astrocytes B) Dorsal horn microglia stained for IBA-1 C) Ependymal 
cells stained for Vimentin surrounding the central canal of the spinal cord.  
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1.2.1 Astrogliosis 
Reactive astrogliosis (or astrocyte reactivity) is a process by which astrocytes undergo a 
series of morphological, cellular, molecular and functional changes in response to injury or 
disease [57]. These changes occur in a context-specific manner and take place in a graded 
fashion according to the severity of the insult, and they can affect surrounding tissue in a 
beneficial or detrimental way [10]. Mild to moderate reactive astrogliosis is characterized 
by upregulation of genes such as GFAP (the most commonly used hallmark of reactive 
astrocytes) and hypertrophy of the cell body and processes. Despite this, astrocytes preserve 
their non-overlapping individual domains and astrocyte proliferation is minimal or absent. 
This type of astrogliosis has the potential to resolve if the triggering insult ceases [10, 11, 
57]. However, with overt tissue damage and inflammation, reactive astrogliosis can become 
severe, in which case astrocytic processes start to overlap into each other’s domains. This 
event is often accompanied by extensive astrocyte proliferation and tissue re-organization. 
Moreover, astrocytes (including those newly proliferated) can gather around the borders of 
the damaged tissue and interact with other cell types to form glial scars (discussed later on). 
Structural changes associated with severe astrogliosis are persistent and do not resolve even 
if the initial insult is no longer present [10, 11, 57]. 
1.2.2 Microgliosis 
Microglia, unlike other glial cell types, are particularly sensitive to alterations in the 
extracellular environment. Consequently, they are typically the first cell type to respond 
after injury or disease [58]. Reactive microglia undergo multiple changes, including the 
upregulation of surface antigens and receptors that are characteristic of innate immune 
responses. For example, microglial cells can take part in antigen presentation by 
upregulating major histocompatibility complex (MHC) class II molecules [59-61]. Reactive 
microglia alter their morphology and transform from a ramified to a more amoeboid shape. 
Cell bodies become enlarged and microglial cell processes become thicker and shorter, 
reducing the area that they normally cover [44]. This configuration is associated with a high 
degree of microglial activation, which is characterized by phagocytosis and pro-
inflammatory functions [62]. Moreover, microglia markedly proliferate to increase their 
numbers, which potentiates their response after an insult [58, 63]. 
 
Ionized calcium binding adapter molecule 1 (IBA-1) is a common marker for resting 
microglia [64]. However, since this protein is well distributed around the cytoplasm and 
processes of microglial cells, it allows the visualization of morphological changes 
associated with microgliosis with ease [65]. Moreover IBA-1 reactivity increases in 
reactive microglia, hence this protein is often used as a marker of microgliosis [64, 65]. A 
similar marker used is CD11b, which in rats can be detected with a monoclonal antibody 
known as OX42 (see Study I). It is important to mention that the marker profile of 
microglia and blood-derived macrophages is remarkably similar. Therefore, when 
macrophages infiltrate the CNS, it becomes a daunting task to distinguish these two 
populations. The scientific community has tried to addressed this problem by identifying 
proteins that are more highly expressed in microglia, and to develop antibodies that can 
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target them specifically. Promising candidates include the Fc receptor-like S, scavenger 
receptor (Fcrls; used in Study IV), transmembrane protein 119 (Tmem119) or P2Y12 
purinergic receptor (P2Y12R), which, in some contexts and with particular techniques can 
serve to discriminate resident microglia from blood-derived macrophages [66, 67]. 
1.3 SPINAL CORD INJURY 
Every year, 54 people per million (mostly young or older males) suffer from traumatic 
spinal cord injury (SCI) in the U.S. alone, due to vehicle accidents, falls, violence and sport 
incidents [68]. SCI often leads to paralysis below the injury level and results in sensory and 
motor problems deficits of variable degree. Some of these include breathing difficulties, 
loss of bladder and bowel control, numbness, emotional changes and chronic pain. Despite 
medical advances, there is still no cure for SCI [69, 70].  
 
Traumatic SCI occurs when an initial mechanical insult results in the compression, 
contusion or laceration of the spinal tissue. This initial insult damages neurons and 
surrounding glia, disrupts the vasculature and causes ischemia and edema [71, 72]. Tissue 
damage and cell death get exacerbated as a result of secondary events that include sustained 
inflammation, excitotoxicity and loss of blood-spinal cord barrier integrity [73-76]. 
Multiple cell-types get recruited to the injury site, coming both from the periphery and the 
spinal cord itself. Immune cells such as neutrophils, macrophages and lymphocytes 
infiltrate the spinal parenchyma and accumulate in the core of the lesion [77]. Moreover, 
through the release of pro-inflammatory factors, activated microglia/macrophages promote 
vascular permeability and the recruitment of more immune cells to the lesion epicenter. 
Even though such immune response is vital for the clearance of debris and degenerating 
tissue, it creates a hostile inflammatory environment that aggravates ongoing apoptosis and 
tissue damage [78-80]. This sustained cellular death promotes the formation of cystic 
cavities that are mainly comprised of extracellular fluid [72]. Additionally, activated 
macrophages, but not microglia, can phagocytose axonal fragments in areas of severe 
inflammation, contributing to the axonal dieback of injured neurons [81-83]. Following 
SCI, astrocytes become reactive and contribute to the formation of a glial scar (Figure 3) 
that surrounds the lesion core (discussed later on) [57]. Moreover, ependymal cells also get 
activated, increase their proliferation and migrate towards the lesion epicenter, mostly 
giving rise to scar-forming astrocytes (see below) [24, 30]. A fibrotic scar also develops at 
the lesion core, which is characterized by excess deposition of extracellular matrix 
molecules by stromal cells that invade the lesion epicenter [84-86]. In penetrating injuries 
where the meninges are disrupted, meningeal fibroblasts have been observed in the lesion 
core [84]. Additionally, in this type of injury, stromal cells derived from type-A pericytes 
can also infiltrate the lesion epicenter and contribute to the fibrotic scar. In fact, genetic 
ablation of type-A pericyte progeny results in an incomplete closure of the lesion [85]. 
Another study has reported that in response to contusion SCI, where the meninges are 
intact, perivascular fibroblasts are another major cell population that participates in the 
fibrotic scar [86]. Of note, NG2 oligodendrocyte progenitors can also proliferate and 
migrate towards the lesion core in response to injury [87]. For instance, it is thought that a 
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subpopulation of these cells is able to stabilize dystrophic axons within the aggressive 
inflammatory environment present in the lesion core [88, 89]. Moreover, NG2 
oligodendrocyte progenitors found in demyelinated areas can differentiate into mature 
oligodendrocytes and contribute to axonal remyelination [90-92]. However, newly 
synthetized myelin sheets display immature structural properties and might not provide a 
complete restoration of axonal conductance [93].  
 
Although there is no treatment for SCI, many clinical trials are ongoing. Current efforts are 
typically aimed at protecting spared tissue, promoting axonal regeneration and replacing 
lost nerve cells [71]. Indeed, experimental approaches have demonstrated that axonal 
regeneration through the inhibitory environment found in the lesions is actually possible 
[94]. Some of the most attractive regenerative strategies include stem cell/progenitor 
transplantations, endogenous stem cells/progenitor modulation, delivery of neurotrophic 
factors, peripheral nerve bridges, electrical stimulation and blockade of growth inhibiting 
factors [95, 96].  
1.3.1 Astrocytes in SCI 
Astrocytes located in the vicinity of the lesion site respond to injury-induced factors by 
becoming reactive. A graded degree of astrogliosis is commonly observed, which ranges 
from mild to severe depending on the proximity to the lesion core [11]. Astrocyte migration 
and proliferation around the margins of the lesion epicenter initiate the formation of an 
astrocytic scar [97-99]. Such astrocytic proliferation is rather moderate, peaking one week 
after injury and gradually declining after that [100-102]. The astrocytic scar consists of a 
mesh-like structure of intermixing hypertrophic cellular processes, which creates a physical 
Figure 3 Diagram depicting the layered architecture of the glial scar in a contusive SCI. The lesion penumbra is 
comprised of reactive astrocytes (astrocytic scar) while the lesion core contains NG2 oligodendrocyte progenitors 
associated to dystrophic axons, leukocytes (not depicted), microglia/macrophages and fibroblasts/stromal cells. Reprinted 
from Cregg J.M. et al; Functional regeneration beyond the glial scar Experimental Neurology. 253:197-207 © 2014 with 
permission from Elsevier.   
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barrier between the core lesion and the surrounding parenchyma. This scar is typically 
formed two weeks after injury and matures after three weeks [57]. It has been estimated 
that around 85% of the astrocytes that comprise the astrocytic scar are newly proliferated 
[103].  
 
The role of reactive astrocytosis and astroytic scar formation has been subject for debate 
over the years, and while it was first associated with detrimental effects, beneficial roles 
have also been described. For instance, by creating a barrier between the injured area and 
the healthy parenchyma, the astrocytic scar confines intense inflammatory processes to the 
lesion epicenter while limiting the spread of immune cells or damaging factors towards 
unaffected areas [57]. Certainly, inhibiting the formation of the astrocytic scar exacerbates 
tissue damage, cell death and demyelination, due to widespread inflammation and aberrant 
blood-spinal cord barrier permeability that result in larger lesions and a worse functional 
outcome [97-100, 104, 105]. On the other hand, reactive astrocytes can release molecules 
that have inhibitory effects towards axonal regeneration, such as for example, chondroitin 
sulphate proteoglycans (CSPG). Of note, enzymatic depletion of CSPG promotes axonal 
regeneration and results in improved locomotor recovery [106]. Furthermore, factors 
released by astrocytes, such as cytokines, can aggravate inflammatory processes and 
enhance the production of molecules such as ROS and glutamate that become neurotoxic at 
elevated levels, exacerbating tissue damage around the lesion [11].  
 
Altogether, reactive astrocytes appear to play a crucial role in protecting spared intact tissue 
from inflammatory processes. However, this beneficial effect seems to come with the cost 
of inhibiting axonal regeneration.  
1.3.2 Ependymal cells in SCI 
Upon SCI, ependymal cells become activated and undergo transcriptional changes that 
result in the upregulation or de novo expression of proteins such as GFAP and Nestin [26, 
107, 108]. Moreover, their ability to form neurospheres in vitro is greatly enhanced upon 
injury [30]. In most experimental models of SCI, the proliferation of ependymal cells 
begins 24 hours after SCI, peaking 3 days after injury and gradually returning to basal 
levels within three to four months. Of note, transection models (penetrating injuries) often 
present a greater albeit shorter and more localized proliferative response than contusion or 
compression models (non-penetrating injuries) [109]. There is conflicting evidence as to 
whether the ependymal layer must be directly damaged to induce ependymal proliferation. 
While some groups have reported ependymal proliferation exclusively after directly 
lesioning these cells [103, 110], others have observed ependymal proliferation when 
eliciting injuries that do not reach the ependymal layer [24, 28, 30, 111]. Interestingly, 
ependymal proliferation rates have been correlated with motor function recovery in studies 
carried out in rodents [108, 109] and lower vertebrates [112, 113].  
 
In addition to their proliferative response, ependymal cells can generate progeny of the glial 
lineage, mainly comprised of astrocytes [24, 28, 30, 103, 111] and a small percentage of 
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oligodendrocytes [24, 30]. In transection models, the newly generated ependymal-derived 
progeny migrates towards the center of the transection gap and contribute to the glial scar 
with one third to half of all the scar-forming astrocytes [30]. Ependymal-derived astrocytes 
express lower levels of GFAP in relation to vimentin, which is indicative of a more 
immature phenotype. Interestingly, these astrocytes do not appear to secrete CSPGs and 
thus do not interfere with axonal sprouting [24]. Notably, recent reports using compression 
SCI have shown that ependymal cells do not migrate extensively and that their contribution 
to glial scar formation is much more limited than in transection models [103, 114].  
 
Taken together, it is evident that the ependymal response differs according to the severity 
and the injury type. Nevertheless, these cells have the capability of proliferating, migrating 
and differentiating intro other cells types in vivo, although the proportion of the progeny 
produced may differ. It is important to mention that while ependymal cells in vitro can 
differentiate into neurons, this is not the case in the intact or injured spinal cord in vivo [24, 
28, 30, 111]. This suggests that the extracellular milieu influences or may even dictate the 
fate of the ependymal cell progeny and may hinder ependymal differentiation into neurons. 
Indeed, the disparities in the ependymal cell response that are observed among injury 
models might also be explained by intrinsic differences in the extracellular environment.  
 
The fact that ependymal cells are essential for the complete repair of the CNS in lower 
vertebrates [112, 115] has recently attracted scientists to decipher the function of these cells 
in adult mammals. A growing body evidence indicates that ependymal cells have beneficial 
effects in rodent models of SCI. Interestingly, genetic ablation of ependymal-derived 
progeny has revealed that these cells are important for restricting neuronal loss and 
secondary tissue damage that could result in larger lesions [116]. Moreover, ependymal 
cells appear to be essential for sealing off the disrupted central canal after SCI [103]. In 
addition, experimental transplantation of adult spinal cord-derived neural stem cells into the 
injured spinal cord can promote functional recovery [117]. These concepts demonstrate that 
ependymal cells have the ability to facilitate tissue repair in adult mammals, making them 
an attractive target for the treatment of SCI.  
 
Strategies aimed at modulating ependymal cells in situ hold great promise, as ependymal 
cells could potentially be reprogrammed to differentiate into neurons and oligodendrocytes 
to enhance tissue regeneration [118]. Indeed, the study of ependymal cells in an injury 
setting would be essential for elucidating mechanisms that facilitate ependymal cell 
reprogramming in a milieu that does not favour neurogenesis. In Study II, we have 
addressed this need by establishing an accessible ex vivo model that allows the study and 
modulation of ependymal cells in an environment that resembles that of an injury state.  
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1.3.3 IL-6 and SCI 
IL-6 is a pleiotropic cytokine that plays an important role in response to injury. Current 
evidence suggests that IL-6 can have a dual role in regeneration, depending on the degree, 
temporal expression and the balance between neurotoxic and neuroprotective effects [119-
121]. During the early stages of SCI, IL-6 potentiates the inflammatory cascade and 
negatively affects axonal regeneration by promoting glial scar formation [122]. On the 
other hand, several studies have also suggested that IL-6 can act as a neuroprotective factor 
promoting axonal regeneration. IL-6 application has been shown to reduce ischemic brain 
damage in vivo and N-methyl-D-aspartate (NMDA) receptor mediated excitotoxicity in 
vitro [123-125]. Moreover, mice constitutively expressing IL-6 have a faster regeneration 
of the hypoglossal nerve after trauma [126]. Noteworthy, it has been showed that injection 
of a cytokine cocktail containing IL-6 in mice 1 day after SCI promoted microglia and 
macrophage activation and recruitment to the spinal cord, exacerbating the initial immune 
response. However, if the cytokine cocktail was injected 4 days after SCI, it resulted in a 
decreased activation of microglia and a smaller injury size [119]. Therefore, stimulation of 
IL-6 production in the spinal cord in a time-controlled manner could be a promising 
strategy to improve recovery after SCI. 
1.3.4 mTOR signalling 
The mechanistic target of rapamycin (mTOR) is a serine-threonine kinase that regulates 
fundamental cell processes such as protein synthesis, autophagy, proliferation and 
metabolism (see Figure 4). mTOR is the enzymatic component of two functionally distinct 
protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [127].  
 
mTORC1 is a main downstream component of the phosphoinositide 3-kinase (PI3K)-AKT 
pathway and it regulates protein synthesis through phosphorylation of p70 ribosomal S6 
kinase (p70S6K), which in turn phosphorylates the ribosomal protein S6. Consequently, 
phosphorylated (p-) S6 is often used as a readout of mTORC1 activity [128]. mTORC1 
activity can be blocked by rapamycin, which binds FK506-binding protein of 12 kDa 
(FKBP12) forming a complex that inhibits mTOR only when it is part of mTORC1 [129]. 
Importantly, rapamycin can have additional effects that are independent of mTORC1 
blockade, which are further discussed in Study I.  
 
mTORC2 is also involved in the PI3K-AKT pathway although its activity is independent of 
mTORC1. This complex can phosphorylate and facilitate AKT activation, thus playing a 
fundamental role in AKT mediated cell survival [130, 131]. Currently, there are no specific 
blockers of mTORC2 activity. However, competitive inhibitors like torin2 act by blocking 
the ATP-binding site of mTOR, which inhibits its activity whether it forms part of 
mTORC1 or mTORC2 [132]. Nevertheless, due to the similarity between mTOR and PI3K 
sequences, many ATP competitive inhibitors that target mTOR, including torin2, also 
inhibit PI3K activity [133]. 
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Current evidence shows that mTOR can regulate IL-6 expression negatively or positively 
depending on the cell type [134]. For example, in myeloid phagocytes the mTOR pathway 
negatively regulates IL-6 production [135] while in endothelial cells, mTOR has been 
found to positively influence IL-6 synthesis [136]. In Study I, we examine the role of 
mTOR in regulating IL-6 expression and secretion in astrocytes, and study the relationship 
between IL-6 and mTOR in astrocytes in the context of SCI. 
1.4 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that affects 
approximately 1% of the population, with a higher prevalence in women than in men (3:1) 
[137]. The etiology of this disease remains unclear, although genetic and environmental 
factors such as HLA-DRB1 shared epitope alleles and cigarette smoking have been 
associated with a higher risk to develop RA [138-140]. This autoimmune disease affects 
mainly the joints and it is characterized by aggressive synovial inflammation (synovitis), 
local infiltration of immune cells and joint swelling, which often leads to a progressive 
destruction of cartilage and bone [141]. The identification of biological disease modifying 
anti-rheumatic drugs have led to great improvements in RA prognosis, since they can slow 
down or even halt disease progression in a vast majority of RA patients [142]. However, as 
further discussed below, chronic pain continues to be the most debilitating problem 
reported by RA patients [143, 144].  
Figure 4 Schematic diagram illustrating members of the P3IK-mTOR-AKT pathway (simplified) that were investigated 
in Study I. Albeit not shown here, rapamycin can also induce mTORC2 and pyruvate dehydrogenase kinase isozyme 1 
(PDK1) activation in astrocytes. Moreover, torin2 can also inhibit PI3K and AKT (see Study I). Relevant phosphorylation 
sites on serine (S) or threonine (T) are indicated on activation (black) arrows.  
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1.4.1 Autoantibodies in RA 
A large proportion of RA patients produce autoantibodies, which can be found in synovial 
fluid and in blood circulation [145, 146]. Moreover, in Study III we also report the 
presence of autoantibodies in the CSF of certain RA patients. There is a large number of 
autoantibodies against different self-antigens that are associated with RA, including 
rheumatoid factor, antibodies against collagen type-II and anti-citrullinated peptide/protein 
antibodies. Although circulating autoantibodies are often used as diagnostic markers of RA 
[146], their contribution to pathology is not always clear.  
 
Rheumatoid factor (RF) was the first autoantibody detected in RA patients, serving as the 
only available serological marker used to diagnose the disease. However, it is now clear 
that RF is not specific to RA since it has been identified in other autoimmune conditions 
and even in healthy individuals. RF recognizes and interacts with the Fc (fragment, 
crystallizable) region of Immunoglobulin G (IgG), leading to the formation of immune 
complexes that are thought to contribute to RA pathogenesis. The presence of RF is 
associated with more severe and destructive forms of RA [147-150].   
 
Collagen type II (CII) is a major component of joint cartilage. Antibodies against CII can 
be found in RA patients around the onset of the disease, with a prevalence that is highly 
variable [151, 152]. In mice, passive transfer of anti-CII antibodies induces arthritis and 
contributes to synovitis, joint inflammation, pain and to the destruction of cartilage and 
bone, resembling the human pathology of RA [153]. These findings constitute the basis of 
the collagen antibody induced arthritis (CAIA) model, which is suitable for the study of RA 
pathology and pain aspects [154].   
 
Anti-citrullinated peptide/protein antibodies (ACPA) are found in about 60-70% of RA 
patients and are routinely used as a diagnostic marker for RA [146, 155]. Citrullination is a 
post-translational modification that consists in the enzymatic conversion of arginine 
(positively charged) to citrulline (neutral). This change in amino acid net charge is thought 
to affect the structure and function of the protein, leading to an increase in its 
immunogenicity. RA is associated with aberrant levels of protein citrullination and some of 
the most common citrullinated proteins present in RA patients are CII, vimentin, ⍺-enolase, 
fibrinogen and histone 4 [156, 157]. 
 
The role of ACPA on RA pathology has recently started to be elucidated. ACPA can be 
detected up to several years before the onset of RA although higher titers and epitope 
spreading is commonly observed when individuals approach disease diagnosis [158, 159]. 
ACPA positive individuals can present arthralgia (bone pain) and bone erosion before the 
development of RA, and these autoantibodies are also associated with a more aggressive 
RA course [160-162]. Such observations suggest that ACPA play an important role in 
driving RA pathology. Interestingly, recent experimental studies that support this notion 
have delineated the mechanisms behind ACPA’s ability to mediate pain and bone 
destruction in the absence of synovial inflammation [163, 164].  
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Figure 5 A) IgG structure. The variable regions (depicted in red) of the light (purple) and heavy (blue) chains form the 
Fab region which can recognize and bind antigens. The constant regions of the heavy chains at the other end comprise the 
Fc portion, which can engage in effector functions B) Antigen-antibody complexes, also known as immune complexes are 
often needed to activate certain receptors, such as FcγRs  
1.4.2 Mechanisms of antibody action 
Antibodies, also known as immunoglobulins (Ig), are the main effector molecules of the 
adaptive immune system. They can be classified into five isotypes (IgG, IgA, IgE, IgM and 
IgD) which have different characteristics. IgG is the most abundant antibody in circulation 
and the work presented in Study III and IV revolves around this particular isotype [165].  
 
Antibodies can recognize and bind antigens with the Fab (fragment, antigen-binding) 
region, which is essential for mediating the clearance of pathogens. Fc-receptors found in 
immune cells can potentiate antibody-mediated effector functions by interacting with the Fc 
region of antibodies (Figure 5) [165].  
 
Fc-receptors are classified according to the antibody isotype that they recognize. In 
humans, Fc-gamma receptors (FcγRs) can be further subdivided into 6 types (FcγRI, 
FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB) each of which has a different 
molecular structure and affinity for IgG. Notably, FcγRs can only be activated by immune 
complexes and not by monomeric IgG [166]. Albeit most of our knowledge regarding 
FcγRs come from findings made in immune cells, the presence of this class of receptors has 
also been reported in cell types such as neurons and glia [167-170]. Of particular interest is 
the FcγRI, which has the highest affinity for IgG and has been implicated in pain signalling 
in cultured neurons [167] and in an experimental model of arthritis [168].  
1.5 PAIN 
1.5.1 Acute and chronic pain 
Pain is a normal physiological response that acts as a warning’s system helping us to 
prevent tissue damage and to attend and protect wounded areas. Pain transmission is 
mediated by sensory neurons called nociceptors, which can convert mechanical, chemical 
and thermal stimuli into electrical signals. These pain signals are then relayed to the spinal 
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cord dorsal horn, which further convey the information to the brain, where the pain is 
perceived. Acute pain usually lasts until the noxious stimulus or the tissue damage have 
resolved. However, persistent nociceptive stimulation can result in a dysregulation of 
normal pain processing and lead to the development of chronic pain [171, 172]. 
 
Chronic pain refers to pain that lasts longer than 3 months and does not resolve on its own 
[172].  It is a debilitating condition that affects between 11.5% and 55.2% of the population 
and has a greater prevalence among women than men [173, 174]. Currently, treatment 
options for chronic pain are suboptimal, as these patients do not respond adequately to 
existing analgesics. As a consequence, people with chronic pain commonly have a lower 
quality of life with significant functional, social and emotional complications [175]. 
Chronic pain is characterized by processes such as hyperalgesia (increased pain sensitivity 
to painful stimuli), allodynia (pain sensation to a stimulus that does not normally induce 
pain) and spontaneous pain. The mechanisms responsible for these maladaptive pain states 
can be peripherally or centrally driven [176, 177]. Peripheral sensitization occurs when 
nociceptive terminals become hypersensitive as a result of a higher or sustained activation 
caused by factors in the injured area. On the other hand, central sensitization occurs as a 
result of changes that increase the excitability of dorsal horn neurons and amplify the pain 
signal (Figure 6). Different processes can lead to central sensitization. For example, 
persistent transmission of nociceptive signals from the periphery can facilitate 
glutamatergic signalling, dysregulate pain inhibitory pathways, and lead to the activation of 
glial cells in the dorsal horn, which further promotes the enhancement and maintenance of 
pain states. [175-178]  
Figure 6 Schematic diagram showing peripheral and central sensitization processes in the context of RA. Nociceptive fibers 
that innervate bone structures include unmyelinated C-fibers (red) and myelinated A∂ fibers (blue). Persistent activation of 
nociceptors by inflammatory factors in the joint can lead to peripheral sensitization. Such nociceptive signals travel via the 
dorsal root ganglia (DRG) to the dorsal horn of the spinal cord, where they can become amplified and cause central 
sensitization. Glial cells such as microglia and astrocytes can contribute to central sensitization. Diagram based on Figure 1 
from Jie Su’s dissertation: Chronic pain and arthritis – studies of mechanisms in the regulation of hypersensitivity, 
Karolinska Institutet, 2016.  
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1.5.2 Neuropathic, inflammatory and arthritic pain 
Chronic pain can be divided into several types according to its cause. Neuropathic pain 
arises when nerves in the peripheral or central nervous system become damaged by a 
traumatic injury or due to disease pathogenesis. Increased hypersensitivity occurs as a result 
of the aberrant pain signalling that takes place in the lesioned axons but also in the intact 
nociceptors that innervate the same territory as the injured nerve. This type of pain is 
commonly associated with conditions such as spinal cord injury, diabetes and autoimmune 
diseases [179].  
 
Chronic pain can also be inflammatory, where pain-promoting factors found in the inflamed 
area can activate and sensitize nearby nociceptors. Inflammatory pain is an important 
component in RA. However, the pain phenotype of RA patients is complex and there is 
little correlation between disease activity and pain [180, 181]. For instance, a considerable 
proportion of RA patients continue to have pain even when the disease and the 
inflammation are medically under control or in remission [180, 182]. Moreover, the 
development of arthralgia often precedes synovitis and it is a predictive factor for RA [160, 
183]. Additionally, RA patients can experience generalized hypersensitivity at distant areas 
from the affected joint [184-186], suggesting that central sensitization plays an important 
role in this condition [187]. Our current knowledge about arthritic pain has been greatly 
advanced with the use of poly-arthritic animals models which present pain phenotypes that 
closely reflect the clinical scenario. In Study IV, we have used the CAIA model, which is 
characterized by transient joint inflammation and persistent mechanical hypersensitivity. 
Interestingly, while it has been shown that nonsteroidal anti-inflammatory drugs can 
attenuate arthritis-induced hypersensitivity during the phase of joint inflammation 
(inflammatory phase), this is certainly not the case for the late phase of the model, when 
joint inflammation has resolved but mechanical hypersensitivity persists [154]. These and 
similar findings from other models of poly-arthritis suggest that arthritic pain has a non-
inflammatory component, possibly reflecting the situation in RA patients [188]. Supporting 
this notion, our group has reported that passive transfer of ACPA from RA patients into the 
blood circulation of mice leads to thermal and mechanical hypersensitivity without causing 
any visual signs of inflammation [163]. Of interest, in Study III we investigate a possible 
role of these autoantibodies in mediating central sensitization by acting on glial cells. 
1.5.3 Glia in neuropathic, inflammatory and arthritic pain 
A growing body of evidence suggests that spinal glia play important roles in the 
maintenance of chronic pain. Both astrocytes and microglia can be activated in response to 
mediators centrally released by sensitized peripheral nociceptors, as shown in different 
models of neuropathic, inflammatory and arthritic pain. In turn, activated glia can 
synthesize and release cytokines, chemokines and other mediators that further potentiate the 
transmission of pain signals by increasing the excitability of dorsal horn neurons or by 
decreasing inhibitory neurotransmission. Moreover, glia-glia interactions can also 
contribute to central sensitization. Several receptors, signalling pathways and cytokines 
appear to be implicated in the regulation of pain transmission by glial cells [175, 189]. 
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 One of the most-well documented pathways driving pathological pain is mediated by the 
chemokine fractalkine, also known as CX3CL1. These chemokine is expressed by 
excitatory dorsal horn neurons, and, upon cleavage by cathepsin S, it becomes soluble and 
binds to its receptor CX3CR1, which is located in microglia. Microglial activation of 
CX3CR1, which is upregulated in experimental pain models, leads to the phosphorylation 
of p38 and a subsequent release of pro-nociceptive cytokines such as IL-6 and interleukin-
1beta (IL-1ß) [190-192].   
 
Purinergic receptors, which become upregulated upon injury, have also been associated 
with pain transmission [193]. For instance, ATP activation of P2X7R expressed in 
microglia can regulate the secretion of cathepsin S (promoting the cascade of events 
explained above) and also mediate the microglial release of the pro-nociceptive cytokine 
IL-1ß [194]. ATP can also activate P2X4 purinergic receptors (P2X4R) on microglia, and 
pharmacological inhibition of this receptor leads to a transient attenuation of mechanical 
hypersensitivity [195]. Moreover, P2X4R and P2X7R knockout mice develop less 
allodynia after peripheral nerve injury [196, 197]. A proposed mechanism by which P2X4R 
may contribute to neuropathic pain is by the release of microglial brain derived 
neurotrophic factor (BDNF), which binds tyrosine receptor kinase B (TrkB) and leads to 
the downregulation of potassium-chloride co-transporters (KCC2). This results in an 
accumulation of chloride ions in dorsal horn neurons, which, upon γ-aminobutyric acid 
binding, become depolarized instead of hyperpolarized [198].  
 
Importantly, toll-like receptors (TLR) expressed in astrocytes and microglia including 
TLR2, TLR3 and TLR4 can also contribute to glial activation and to the maintenance of 
neuropathic, inflammatory and arthritic pain [199]. For instance, attenuation of spinal 
gliosis and mechanical hypersensitivity have been reported in TLR4 knockout mice 
subjected to K/BxN serum transfer arthritis [200]. Moreover, central administration of 
TLR4 ligands such as lipopolysaccharide (LPS) or high-mobility group box-1 (HMGB1) 
can induce mechanical hypersensitivity, and pharmacological inhibition of either of these 
factors in models of neuropathic or arthritic pain can reduce spinal nociceptive signalling 
and suppress glial activation [201-203]. Other TLR4 ligands, such as heat shock protein 90 
(hsp90) have also been associated with altered pain processing and glial activation [204-
206]. 
 
Of note, activation of astrocytes in models of nerve injury-induced pain has been associated 
with down-regulation of glutamate transporters, resulting in increased extracellular levels of 
extracellular glutamate that facilitate neuronal excitability and spinal nociceptive signalling 
[207]. However, glutamate transporter down-regulation has not been reported in 
inflammatory pain models, and the role of such receptors in arthritis-induced pain remains 
unclear.  
 
Two different members of the mitogen-activated protein kinase (MAPK) family have been 
extensively studied in relation to altered pain processing; p38 and c-Jun N-terminal kinase 
(JNK). Even though p38 can be constitutively expressed in microglia and astrocytes, this 
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intracellular factor intriguingly undergoes phosphorylation (activation) exclusively in 
microglia in chronic pain models, including arthritis-induced pain models [208, 209]. 
Interestingly, p38 is involved in several signalling processes that facilitate pain 
transmission, such as the CX3CL1-CX3R1 and ATP-P2X4R-BDNF pathways described 
above [175]. Phosphorylation of astrocytic JNK has been reported in animal models of 
inflammatory and neuropathic pain [210, 211]. Indeed, intrathecal administration of JNK 
inhibitors attenuates neuropathic and inflammatory pain [211, 212]. Of note, spinal JNK 
blockade has also been reported to reverse mechanical hypersensitivity during the late 
phase of the CAIA model [154]. Nevertheless, whether p-JNK is restricted to astrocytes in 
this model remains to be determined. Just like p-p38, p-JNK is involved in the production 
and release of pro-nociceptive cytokines [199]. 
 
Lastly, the role of cytokines in facilitating and perpetuating altered spinal pain is worth 
mentioning. Both microglia and astrocyte can produce and secrete pro-nociceptive 
cytokines, including for example IL-1ß, IL-6 and TNF [175].  
 
The pro-inflammatory cytokine IL-1ß was one of the first cytokines described to participate 
in the mechanisms underlying neuropathic pain [213]. Under physiological conditions, the 
expression of IL-1ß by glial cells and neurons is quite low, although pathological events 
can trigger its upregulation [175]. Importantly, IL-1ß has been detected in patients with 
diverse painful neuropathies and in individuals with RA [214-216]. Similarly, several 
models of arthritis have reported the presence of IL-1ß in the CSF of these animals, which 
is concomitant with glial activation and the development of hypersensitivity [216, 217]. 
Evidence for the pro-nociceptive effect of IL-1ß come from studies where central 
administration of exogenous IL-1ß led to mechanical and thermal hypersensitivity [218, 
219] and from the observation that rodents lacking IL-1ß had diminished pain-like behavior 
after peripheral nerve injury [220]. Of interest, a recent study has suggested that collagen 
induced arthritis (CIA) induced pain is associated with central sensitization events that are 
dependent on the microglial release of IL-1ß [217]. IL-1ß can facilitate spinal nociceptive 
processing by activating NMDA receptors, leading to increased dorsal horn neuronal 
excitability. Furthermore, it is also thought that IL-1ß can also promote pain transmission 
by reducing inhibitory neurotransmission [221].  
  
Mounting evidence suggests that IL-6 plays a crucial role in pathological pain processing 
[222-224]. IL-6 acts by binding to IL-6 receptors (IL-6R) which can be membrane bound or 
soluble. The pro-nociceptive effects that IL-6 exerts in neurons are caused via the soluble 
IL-6R, as these cells lack membrane-bound IL-6 receptors [225]. Importantly, elevated 
levels of IL-6 and its receptor have been found in the spinal cord of various pathological 
pain models, and there is evidence supporting the contribution of IL-6 to peripheral and 
central sensitization [222, 226]. IL-6 is also associated to glia activation, as demonstrated, 
for example, in transgenic mice that overexpress IL-6, which show prominent signs of 
astro- and microgliosis [227]. Evidence for a role of IL-6 in central sensitization come from 
studies which show that spinal administration of IL-6 can elicit thermal and mechanical 
hypersensitivity [222, 225]. Additionally, IL-6 knockout mice exhibit reduced pain-like 
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behavioral responses in different nerve injury models, and inhibition of IL-6 signalling with 
different compounds applied intrathecally can attenuate pain behavior in models of 
peripheral nerve injury, spinal cord injury and arthritis [228].  
 
Lastly, intrathecal administration of compounds such as fluorocitrate, pentoxifylline or 
minocycline, which can inhibit glial activity despite having many off-target effects, prevent 
or reverse the initiation and maintenance of persistent pain states in a myriad of models of 
neuropathic, inflammatory and arthritic pain [154, 189, 193, 199, 229]. Thus, these findings 
further suggest that glial cells play an active role in spinal pain transmission.  
1.5.4 Glial sex-differences in relation to pain 
Currently, there is an important debate ongoing within the pain research community 
concerning the dimorphic involvement of glial cells in chronic pain. In 2011, an important 
paper by Sorge et al., described that spinal TLR4, which can be found in microglia, could 
mediate neuropathic and inflammatory pain in male, but not female mice [201]. In 2015, a 
collaborative paper that included independent observations from three different 
laboratories, corroborated a male specific microglial involvement in persistent pain states. 
A wide battery of compounds that were able to deplete microglia, inhibit microglial 
function or block crucial signalling molecules were tested, leading to the conclusion that 
the P2X4R-p38-BDNF pathway is an essential driver of inflammatory and neuropathic pain 
in male but not in female mice. Interestingly, in this seminal paper the authors conclude that 
female mice preferentially utilize cells of the adaptive immune system and not microglia to 
drive central sensitization [230]. These premises have led researchers to further investigate 
sex-differences in relation to glia and pain, to only find out that the situation is far more 
complex than initially suggested, with certain discrepancies among different studies. 
 
For instance, Sorge et al., reported that intrathecal injection of LPS (which acts on TLR4) 
causes mechanical hypersensitivity only in male mice, despite normal expression of spinal 
TLR4 in both sexes [201]. On the other hand, Woller et al., have described that intrathecal 
LPS administration induces mechanical hypersensitivity in both sexes, albeit to a greater 
degree in male mice [202]. Adding to this complexity, we have previously shown that 
intrathecal delivery of HMGB1 elicits comparable levels of TLR4-mediated hyper-
sensitivity in male and female mice [203].  
 
Certainly, glial reactivity has been shown to occur to similar extents in male and female 
rodents in several chronic pain models [230, 231](see also Study IV). Nevertheless, 
increasing reports support the notion that male microglia may play a more prominent role in 
pain processing than females. In agreement with the initial findings by Sorge et al., a 
separate study has shown that spinal inhibition of p38 activity can reduce neuropathic and 
inflammatory pain in male but not female rodents, and this effect is likely explained by the 
fact that p38 activation was predominantly observed in male spinal microglia [231]. 
Furthermore, recent work has shown that intrathecal administration of the “microglial 
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inhibitors” minocycline or ZVEID (a caspase-6 inhibitor) reduced inflammatory and 
neuropathic pain exclusively in males [232].  
 
It is important to note that sex-dependent glial signalling has not been examined in a 
systematic fashion in arthritis-induced pain models. Nevertheless, there is some evidence 
suggesting that microglia may mediate pain also in females. For instance, it has been shown 
that intrathecal injection of microglial-targeting drugs, such as P2X7R and cathepsin S 
inhibitors, attenuate the development of mechanical hypersensitivity and dampens 
microgliosis in female rats in the CIA model [12]. Furthermore, we have reported that 
blocking the action of spinal HMGB1 reverses mechanical hypersensitivity in the 
inflammatory and late phases of the CAIA model both in male and female mice [14]. 
Moreover, it has been shown that minocycline can reduce joint nociception when injected 
intrathecally in male mice after antigen-induced arthritis induction (AIA) [36], although the 
effect of minocycline in female mice was not investigated in this particular study. In Study 
IV we have examined male and female microglia from a global perspective, to ascertain 
any possible sex-differences that may be important in the context of arthritis-induced pain.  
 
Notably, whether pain signalling in astrocytes is regulated differently in males and females 
has not been extensively studied. A recent study has addressed this particular question 
using pharmacological compounds to inhibit astrocyte function (L-⍺-aminoadiapate) or 
astrocytic signalling pathways (JNK or ERK inhibitors) involved in pain modulation, 
revealing that the involvement of astrocytes in chronic pain is most likely sex-independent 
[232]. 
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2 AIMS 
2.1 GENERAL AIM 
To investigate the active involvement of glial cells and their cellular responses in 
pathological conditions affecting the central nervous system.   
 
2.2 SPECIFIC AIMS 
• To investigate mechanisms regulating IL-6 expression and release from cultured 
astrocytes in the context of spinal cord injury and rheumatoid arthritis. 
 
• To develop an ex vivo model of spinal cord injury for the study of ependymal cell 
responses. 
  
• To identify potential central effects of anti-citrullinated peptide antibodies found in 
the cerebrospinal fluid of rheumatoid arthritis patients.  
 
• To elucidate critical differences between male and female spinal microglia in the  
context of arthritis-induced persistent pain 
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3 MATERIALS AND METHODS 
3.1 PATIENTS 
Informed consent was obtained from all individuals taking part in Study IV. All 
experiments were approved by the regional ethics committee at Karolinska Institutet and 
carried out in compliance with the Helsinki Declaration. Serum and CSF samples were 
collected from individuals with ACPA-positive rheumatoid arthritis, multiple sclerosis or 
non-inflammatory disease.  
3.2 ANIMALS 
All animal experiments were approved by the Northern Stockholm Animal Research 
Ethical Committee. Animals were housed in groups of 3-5 per cage with food and water ad 
libitum and kept on a 12h light/dark cycle in a climate-controlled environment. In Study I, 
adult Sprague–Dawley rats (Scanbur) were used. In Study II, we used several genetically 
modified mice: 1) hGfap-GFP mice [233], which express green fluorescent protein (GFP) 
under the human Gfap promoter (hGfap); 2,3) mGfap-Cre::GCaMP3 mice and mGfap-
Cre::tdTomato, which express the genetically encoded Ca2+ indicator GCaMP3 or tdTomato 
under the mouse Gfap promoter (mGfap) upon Cre–Lox recombination; 4) hFoxJ1-
CreER::YFP mice [234], where yellow fluorescent protein (YFP) is expressed under the 
human Forkhead Box J1 (hFoxJ1) promoter upon CreER-LoxP recombination induced by 
tamoxifen injection. Adult BALB/cAnNRj mice (Janvier Labs) were used in Study III and 
IV. Adult CBA mice (Harlan) were also used in Study IV.  
3.3 MODEL SYSTEMS 
3.3.1 Adult rat spinal cord primary astrocyte cultures 
For Study I, we used primary rat spinal cord astrocyte cultures which have a similar 
expression profile to human spinal cord astrocyte cultures [235]. Briefly, deeply 
anaesthetized adult rats were decapitated and spinal cords were extruded using a saline-
filled syringe. After removing the meninges, spinal cords were digested with 0.25% trypsin-
EDTA, mechanically triturated and plated in poly-L-lysine coated 175cm2 flasks. Culture 
medium (AM medium containing 2% fetal bovine serum, 1% astrocyte growth supplement 
and 1% penicillin-streptomycin; ScienCell) was replaced every 3-4 days. To remove 
microglia, flasks were shaken for 6 hours at 450 rpm on day 12 and 13, and culture media 
was replaced right after. On day 14 cells were trypsinized and seeded in 6- or 24-well 
plates. Cells were switched to growth factor-free culture medium (DMEM containing 1% 
sodium pyruvate and 1% penicillin-streptomycin; Invitrogen) 48 hours prior drug treatment. 
Cells were kept in a humidified incubator at 37°C (95% air: 5% CO2).  
3.3.2 Human fetal cortical astrocyte cultures 
For Study IV, we used commercially available human fetal cortical astrocytes (ScienCell) 
which can be passaged for up to ten times. Astrocytes were quickly thawed and plated in 
poly-L-lysine coated 75cm2 flasks containing AM medium with 2% fetal bovine serum, 1% 
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astrocyte growth supplement and 1% penicillin-streptomycin (ScienCell). Culture medium 
was changed regularly until cells reached confluency. Cells were then trypsinized, seeded 
in 6-well plates and switched to AM medium with 0.02% fetal bovine serum, 0.01% 
astrocyte growth supplement and 1% penicillin-streptomycin 24 hours prior drug treatment. 
Cells were kept in a humidified incubator at 37°C (95% air: 5% CO2). 
3.3.3 Adult mouse spinal cord slice cultures 
In Study II, we used adult mouse spinal cord cultured slices for the study of ependymal 
cells. Briefly, mice were decapitated under deep anaesthesia and spinal cords were 
hydroextruded with the aid of a syringe. Spinal cords were embedded in 4% low-melting 
agarose in PBS (Sigma) and sectioned into 350µm coronal slices with a vibratome (Leica). 
Slices were transferred to poly-L-lysine coated membranes (Millipore) and placed into 6-
well plates with 1.5ml culture medium containing 50% Neurobasal-A, 25% heat inactivated 
horse serum, 25% HBSS, B-27 supplement, 0.25 mM GlutaMAX, 15 mM glucose, 15 mM 
HEPES and 25 µg/ml penicillin-streptomycin (Invitrogen). Culture medium was replaced 
three times a week (750µl). Cultured slices were kept in a humidified incubator at 37°C 
(95% air: 5% CO2).  
3.3.4 Contusion spinal cord injury  
In contusion injury models (Figure 7), a transient force is applied in order to damage the 
spinal cord. To elicit a contusion spinal cord injury, animals were anaesthetized and a 
laminectomy of the thoracic T9 (rats) or T10 (mice) vertebra was 
performed to expose the dorsal surface of the spinal cord. A 
spinal cord injury was induced dropping a small weight 
from a certain distance using a custom-made (mice) or 
NYU (rats) impactor onto the exposed segment of the 
spinal cord. Pre- and post-operative care, which 
included analgesic treatment and bladder emptying 
(rats), was carried out in accordance to ethical 
guidelines (Study I and II). 
3.3.5 Collagen-antibody induced arthritis  
While this model is commonly used to study RA pathology, it is also suitable for antibody-
induced pain studies. For arthritis induction, mice were injected intravenously (1.25-1.5 
mg) with an anti-collagen type II (CII) cocktail containing 5 different monoclonal 
autoantibodies (Chondrex) followed by an intraperitoneal injection of lipopolysaccharide 
(LPS) from Escherichia coli (25 µg; serotype 0111:B4; Chondrex or 35 µg; serotype 
055:B5; Sigma) 5 days after. Joint inflammation was evaluated visually and scored as 
previously described [154]. Briefly, 1 point is awarded for every inflamed toe or knuckle 
and 2.5 or 5 points for every moderately or severely inflamed ankle or wrist. The maximum 
arthritis score is 15 points per paw and 60 points per mouse (Study IV).  
Figure 7 Schematic representation of a weight-
drop induced contusion spinal cord injury 
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3.3.6 Mice injected with IgG from RA patients  
To assess centrally mediated antibody-induced pain, IgG from plasma and sera of ACPA-
positive RA patients and healthy controls were intrathecally injected into the CSF of 
anaesthetized mice. IgG from RA patients was purified into an ACPA-positive IgG fraction 
and a ACPA-negative IgG fraction containing all remaining IgG (denoted as flow through; 
FT). The purification protocol has been previously described [236] and includes a first 
purification step of IgG with HiTrap Protein G columns (GE Healthcare) followed by a 
second purification step of ACPA positive/negative IgG fractions with an CCP2 affinity 
column (Euro-Diagnostica) (Study III). 
3.4 BEHAVIOURAL ASSESSMENTS 
3.4.1 Mechanical hypersensitivity 
Before testing, animals were allowed to acclimatize for 30-40 min in separate Plexiglas 
compartments with a wire-mesh bottom. Von Frey filaments (Marstock Optihair) of 
incremental force were applied for 2-3 seconds to the plantar surface of the hind paw and a 
positive response was recorded if the paw was withdrawn (Figure 8). The 50% probability 
of paw withdrawal was calculated in grams for each hind paw using the “up-down” method 
[237, 238] and averaged into one score. Results are shown as percentage change of baseline 
values or as the average 50% withdrawal threshold for each group (Study I, III and IV).  
3.4.2 Cold hypersensitivity  
Animals were acclimatized in single wire-mesh bottom Plexiglas cubicles before testing. 
Cold sensitivity was assessed by applying a drop of acetone to the plantar surface of the 
hind paw using a 1ml syringe (Figure 8). The number and duration of nocifensive responses 
(lifting, biting, licking, shaking of the paw) was recorded for 60 seconds. The test was 
repeated three times per paw in an alternating fashion, with a 5-min rest period between 
each testing. Results are shown as the average of the three tests for both hind paws for 
every animal (Study III).   
3.4.3 Heat hypersensitivity 
Mice were allowed to habituate to the wire-mesh bottom Plexiglas cubicles and heat 
hypersensitivity was examined using a modified Hargreaves Box [239]. Briefly, a radiant 
heat stimulus was pointed at the plantar surface of the hind paw until a motion sensor 
detected a brusque paw withdrawal (Figure 8). The time between the start of heat 
stimulation and paw withdrawal was automatically recorded by the sensor. A security cut-
off of 20 seconds was set up to prevent tissue damage. Results are shown as the average of 
three tests for both hind paws for each animal and presented as latency of the withdrawal 
(Study III). 
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3.4.4 Locomotion evaluation  
In Study I, recovery of hind limb locomotor function after spinal cord injury was weekly 
assessed in an open field using the Basso, Beatie, Bresnahan (BBB) rating scale as 
described [240]. Scores 0-9 range from no hind limb movement to stationary weight 
support. Scores 10-21 describe plantar stepping and gait coordination parameters with score 
21 representing normal locomotor function. 
3.5 HISTOLOGICAL, CELLULAR AND MOLECULAR TECHNIQUES 
3.5.1 Tissue processing 
Deeply anaesthetized animals were transcardially perfused with saline solution followed by 
ice-cold 4% paraformaldehyde with or without 0.2% picric acid. Spinal cords were 
dissected, post-fixed and stored in 10-30% sucrose. The tissue was then cut into 14µm or 
20µm coronal sections with a cryostat and mounted on glass slides. For spinal cord injury 
studies (Study I and II), spinal cords were divided in 7mm segments from the center of the 
lesion before sectioning. For studies using mice injected with anti-CII antibodies (Study 
IV), only lumbar spinal cords were processed. 
3.5.2 In situ hybridization 
For Study I, RNA probes for rat IL-6 were made as previously described [241]. Shortly, a 
plasmid containing the full-length cDNA clone of rat IL-6 was linearized with PstI or 
BamHI restriction enzymes. Anti-sense riboprobe was generated by transcription of the 
BamHI digested plasmid with T3 polymerase. Sense riboprobe was synthesized by 
transcription of the PstI digested plasmid with T7 RNA polymerase and were used as 
negative control. Reactions were performed in the presence of digoxigenin-labeled UTP.  
 
For in situ hybridization (Figure 9), slides were permeabilized with PBST (PBS, 0.3% 
Tween-20) and hybridized at 45°C overnight with 10ng/µl of riboprobe in hybridization 
solution containing 4 mM Tris-HCl, 50% formamide, 20% dextran sulphate, 1X Denhard’s 
solution, 0.5 mg/ml Poly-A, 0.5mg/ml salmon sperm, 0.1 M DTT, 0.3 M NaCl and 1 mM 
EDTA. After several washes, slides were incubated with 1X MABT, 2% goat serum and 
2% blocking agent for 1 hour to block non-specific sites. Slides were then incubated 
Figure 8 Behavioral tests. Left panel: Mechanical hypersensitivity was evaluated with Von Frey filaments. Middle panel: 
Cold hypersensitivity was assessed with the acetone test. Right panel: Heat hypersensitivity was examined using a 
modified Hargreaves Box. 
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overnight with an anti-digoxigenin antibody conjugated to alkaline phosphatase (1:2000; 
Roche) and developed for 4 hours in B3 solution (0.1 M Tris-HCl, 0.1 M NaCl, 50 mM 
MgCl2, 0.1% Tween-20) containing the chromogenic substance NBT/BCIP (1:50, Roche). 
Lastly, slides were mounted with glycerol and imaged with an Olympus FV1000 
microscope.  
Figure 9 In situ hybridization for rat IL-6 in naïve and injured spinal cord (SCI) tissue. Figure modified from Study I.  
3.5.3 Slide-mounted immunohistochemistry 
In Study I, II and IV, spinal cord sections were permeabilized with PBST or TBST (PBS 
or TBS, 0.2% Tween-20) and incubated with 5% goat or donkey serum in PBST or TBST 
(blocking solution) for 1 hour to block non-specific binding. Subsequently, spinal cord 
sections were incubated overnight with primary antibodies at 4°C in blocking solution, 
washed several times and further incubated with Alexa Fluor-conjugated secondary 
antibodies (Invitrogen) for 1 hour also in blocking solution. In some instances, slides were 
additionally incubated with DAPI for 30 min in blocking solution. For Study IV, the TSA 
Plus kit (Perkin Elmer) was used as previously described [242]. Briefly, slides were 
blocked in TNB buffer (0.5% blocking reagent in TNT buffer) and incubated for 30 min 
with a horseradish peroxidase-labeled secondary antibody (1:200, DAKO) diluted in TNB 
buffer. Lastly, slides were incubated for 30 min with tyramide-fluorescein diluted in 
amplification solution (1:100). Stained sections were coverslipped with mounting media 
with or without DAPI and images were obtained by epifluorescent (Nikon TE300) or 
confocal microscopy (Olympus FV100, Zeiss LSM710, Zeiss LSM 800). For signal 
intensity quantification images were taken using identical settings. Image analysis and post-
processing was performed using Fiji open-source software [243] or Imaris 7.3.0 (Bitplane).  
3.5.4 Free-floating immunohistochemistry 
Before immunostaining, spinal cord cultured slices were briefly post-fixed in 4% 
paraformaldehyde and incubated for 2 hours with blocking solution (1% goat or donkey 
serum, HEPES buffered HBSS, 0.3% Triton X-100) to mask non-specific binding sites. 
Next, slices were incubated with primary antibodies for 48 hours at 4°C in blocking 
solution, washed several times, and incubated with by Alexa Fluor-conjugated secondary 
antibodies (Invitrogen) for another 48 hours at 4°C in blocking solution. In some cases, 
slides were further stained with DAPI for 1 hour in blocking solution. After several 
washing steps, stained slices were incubated in U2 scale clearing solution (4 M Urea, 30% 
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glycerol, 0.1% Triton X-100) for 1 week at 4°C and mounted onto glass slides. Image 
acquisition and analysis was performed as described in the section above (Study II). 
3.5.5 Calcium imaging  
For Study I, adult rat primary astrocyte cultures were loaded with the ratiometric 
fluorescent dye Fura-2 AM and 0.1% pluronic acid (Invitrogen) in growth factor-free 
culture medium for 30 min, washed several times and imaged in Ca2+-free KREBS-
Ringer´s solution at 37°C with an upright wide-field microscope (AxioExaminer A1, Zeiss) 
equipped with a 20x/1.0 NA water immersion objective. Images were acquired at a 
frequency of 0.5 Hz (Figure 10).  
 
For Study II, adult mice expressing a genetically 
encoded Ca2+ indicator (GCaMP3) under a specific 
promoter were used, enabling Ca2+ imaging in specific 
cell types. Spinal cord slices were attached to the 
imaging chamber with Matrigel (BD Biosciences) and 
allowed to recover for 30 min before imaging. Slices 
were perfused with KREB-Ringer’s solution at 37°C 
throughout the experiment and images were taken every 
15-20 seconds using 40x or 63x water immersion 
objectives mounted on a Zeiss laser scanning 
microscope (LSM510 META NLO) equipped with an 
Argon laser tuned at 488 nm (confocal imaging) or a 
Ti:Sapphire Chameleon Ultra2 laser tuned at 810 nm 
(two-photon imaging).  
 
Ca2+ responses were quantified using Fiji [243] (Study II) or with custom scripts written in 
Phyton (Study I). Basal signals were determined by averaging the pixel intensity of the 
regions of interest for each time point (t) before stimulation (F0). Signal intensity after 
stimulation was determined by dividing the relative changes in fluorescence by F0 for each 
time point (dF/F0).  
3.5.6 Live imaging  
In Study II, long term imaging of spinal cord slices kept in culture was carried out using an 
automated cell culturing system equipped with a 10X air objective (Cell-IQ, Chip-Man 
Technologies). Briefly, freshly prepared slices were positioned inside the Cell-IQ device 
and imaged under stable humidity and temperature conditions for 7 days. Bright-field 
images were taken every 15 hours while fluorescent images were acquired every 8 hours. 
Images were post-processed with the Cell-IQ analyzer software. 
3.5.7 Western blot  
Astrocyte cultures were homogenized in protein extraction buffer containing protease and 
phosphatase inhibitor cocktails (Sigma, Roche) and protein concentration was determined 
Figure 10 Adult rat primary astrocyte 
culture loaded with the Ca2+ indicator 
Fura-2 AM (shown as a heat gradient). 
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using the BCA Protein Assay Kit (Pierce). Proteins were heat-denatured, separated by gel 
electrophoresis (Figure 11; NuPage 4-12% Bis-Tris gel, MES or MOPS running buffer; 
Invitrogen) and transferred to nitrocellulose membranes. Non-specific binding was blocked 
for 1 hour with 5% low-fat milk in TBST (TBS, 0.1% Tween-20). Membranes were 
incubated overnight at 4°C with primary antibodies in 5% 
bovine serum albumin (BSA) in TBST, washed several 
times, and further incubated with horseradish-conjugated 
secondary antibodies (Cell Signalling) for 1 hour in 5% 
BSA TBST. After a few washes, membranes were 
developed with Pierce ECL chemiluminescence substrate 
(Thermo Scientific) using a Bio-rad ChemiDocXRS+ (Bio-
rad). Membranes were stripped with Reblot Western Blot 
Recycling Kit (Millipore) before re-probing with a different 
antibody. Bands were normalized to their respective 
loading controls (e.g. GAPDH) and results presented as a 
percentage of the control experimental condition. Signal 
intensity was quantified using Fiji open-source software 
[243] (Study I and III).  
3.5.8 ELISA-based cytokine and antibody measurements 
The detection of IL-6 from cell supernatants and plasma was carried out using a rat IL-6 
Ultra-Sensitive Kit (Mesoscale Discovery) and a human IL-6 DuoSet ELISA Kit (R&D 
Systems) according to manufacturer’s instructions. 96-well plates were read in a MSD 
Sector Imager 2400 (rat IL-6) or on a Molecular Devices (human IL-6) plate reader.  The 
concentration of each sample was calculated based on the standard curve generated from 
the recombinant protein provided in the kit (Study I, III). 
 
For Study III, human ACPA-IgG levels were determined with a commercial anti-CCP2 
ELISA (Euro-Diagnostica) according to the manufacturer’s instructions. IgG reactivity to 
human influenza was evaluated by H1N1 ELISA as described [244]. Serum was diluted 
1:50 or 1:500 for ACPA or influenza antibody measurements respectively. CSF samples 
were used undiluted. 
3.5.9 Citrullinated peptide microarray  
In Study III, ACPA-IgG binding specificity to the citrullinated peptides α-enolase (CEP-
1), vimentin (Vim60-75), fibrinogen (Fib36-52) and collagen type II (CII C1) as well as to 
their native arginine-containing counterparts was assessed with a custom-made microarray 
based on the Immune CAP ISAC system (Phadia Laboratory Systems) as previously 
described [245]. 
 
Figure 11 Protein separation by gel 
electrophoresis (SDS-PAGE) 
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3.5.10 Fluorescence-activated cell sorting 
Deeply anaesthetized animals were perfused with ice-cold HBSS and lumbar spinal cords 
were flushed out by hydroextrusion. Dorsal horns were dissected and homogenized into a 
cell suspension and myeloid cells were extracted using a 37%/70% Percoll® density 
gradient (Sigma). For some experiments, cells were stained with anti-Fcrls (gift from Dr. 
Butovsky) primary antibody and an APC-conjugated secondary antibody before staining 
with CD45-PE and CD11b-FITC directly conjugated antibodies. Dead cells were stained 
with Sytox blue (Invitrogen). Unstained cells and single staining controls including Sytox 
blue dead stained cells and BD Comp beads (BD Biosciences) for FITC, PE and APC 
fluorochromes were used for compensation. Microglial cells were sorted with a BD Influx 
flow cytometer (BD Biosciences) into RTL lysis buffer (Qiagen) with 1% β-
mercaptoethanol for RNA extraction (Study IV).    
3.5.11 RNA sequencing 
For Study IV, RNA from sorted microglia was extracted using a Qiagen RNeasy® Micro 
Kit and its quantity and integrity was assessed in an Agilent Bioanalyzer (Agilent 
Technologies). cDNA library preparation and RNA sequencing were performed by the 
High Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics 
(Oxford University). The cDNA libraries were synthetized with a SMARTer® Ultra® Low 
Input RNA Kit (Clontech). Samples were amplified and multiplexed on an Illumina 
HiSeq4000 platform to yield 75bp fragments at a depth of at least 27 million reads per 
sample. Quality control was performed using the RSeQC algorithm [246] and reads were 
aligned to the mm10 mouse genome using STAR [247]. Fragments per kilobase of 
transcript per million reads (FPKM) values were obtained using the cufflinks algorithm 
[248] on the Galaxy Freiburg server [249]. Differential gene expression data was generated 
and analyzed with the featurecounts [250] and Deseq2 [251] algorithms. Lastly, interaction 
networks were produced using STRING [252] and edited with Cytoscape [253].    
3.5.12 Real-time PCR  
For Study I and III, adult rat and human fetal astrocyte cultures were lysed in Trizol® 
(Invitrogen) and RNA was extracted using a phenol-chloroform protocol according to the 
manufacturer´s instructions. cDNA was synthesized by reverse transcription using random 
hexanucleotide primers. PCR amplification reactions were performed using TaqMan master 
mix with the primer/probe of interest using a StepOne real-time PCR system (All from 
Applied Biosystems). The standard curve method was used to quantify IL-6. Results were 
normalized to GAPDH values and expressed as relative expression or as a percentage of the 
control experimental condition. 
3.5.13 Luciferase gene reporter assay 
In Study I, cultured rat astrocytes were transfected with a plasmid containing the firefly 
luciferase gene under the control of the wildtype hIL-6 promoter (p1168huIL6P-Luc+) or 
the hIL-6 promoter with a mutated nuclear factor-kappa B (NF-kB) binding site 
(p1168Hil6mNFkB-Luc+). Astrocytes were also co-transfected with a plasmid consti-
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tutively expressing renilla luciferase (pRL-TK). Astrocyte transfection was carried out with 
the Amaxa nucleofector kit (VPI-1006, Lonza) and gene reporter activity was measured 
with the Dual-Luciferase Reporter Assay Sytem (Promega), both according to the 
manufacturer’s protocol. Luciferase activity was measured with a VICTOR2 plate reader 
(Perkin Elmer Wallac). Firefly luciferase activity was normalized to that of the Renilla 
luciferase, to control for transfection efficiency. 
3.5.14 TUNEL assay 
Apoptosis of cultured rat astrocytes was assessed using the Click-iT TUNEL Alexa Fluor 
Imaging Assay (Thermo Scientific) according to manufacturer’s intructions. Treatment 
with DNAse I was used as a positive control. Cells were imaged using a Cell Observer 
(Zeiss) and quantified with a custom pipeline made in CellProfiler [254] (Study I). 
3.5.15 Statistical analysis 
Differences between two groups were performed using the Mann-Whitney U test (non-
parametric, two-tailed) or the unpaired Student’s t-test (two-tailed). Differences between 
more than two groups were analyzed using one-way ANOVA for one independent variable 
(i.e. treatment) and two-way ANOVA for two independent variables (i.e. treatment and 
time). Linear correlation between variables was calculated with the Pearson correlation 
coefficient. Multiple comparison corrections were adjusted using the Bonferroni post-hoc 
test. A P-value < 0.05 was considered significant in all cases. Results are expressed as mean 
± standard error of the mean (SEM). Statistical analyses were performed using Prism 6.0 
(GraphPad).  
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4 RESULTS AND DISCUSSION 
4.1 STUDY I: INTERLEUKIN-6 SECRETION BY ASTROCYTES IS 
DYNAMICALLY REGULATED BY PI3K-mTOR-CALCIUM SIGNALLING 
It has been suggested that the induction of factors promoting regeneration, such as IL-6, in 
reactive astrocytes could be beneficial for tissue recovery. The main goal of this paper was 
to elucidate signalling pathways that regulate IL-6 release in primary rat astrocyte cultures 
(Figure 12), in order to identify potential targets for the modulation of IL-6 in vivo. 
 
Several reports have shown that the mTOR pathway regulates pro-inflammatory cytokine 
production in myeloid phagocytes [255]. Particularly, mTORC1 inhibition by rapamycin 
was reported to increase the levels of cytokines such as IL-6 and TNF-α [135]. In cultured 
astrocytes, we did not observe mRNA IL-6 expression after mTORC1 inhibition by 
rapamycin. However, inhibiting both mTORC1 and mTORC2 using torin2, resulted in IL-
6 induction. Of note, torin2 also inhibited PI3K and AKT signalling cascades, indicating 
that mRNA IL-6 expression is negatively regulated by the PI3K-mTOR-AKT pathway in 
cultured astrocytes.  
 
Next, we aimed to determine whether IL-6 expression was dependent on NF-kB activity, 
since this transcription factor is a potent inducer of IL-6 [256]. Transfection of astrocytes 
with a luciferase gene under the control of a wildtype IL-6 promoter led to higher gene 
reporter activity in torin2-treated astrocytes, as compared to vehicle- or rapamycin-treated 
astrocytes. In contrast, when astrocytes were transfected with an IL-6 promoter containing a 
mutated NF-kB binding site, luciferase expression levels were similar among all conditions. 
Therefore, our data indicates that the PI3K-mTOR-AKT pathway regulates IL-6 
transcription via NF-kB.  
 
Previous work has shown that MAPKs can control IL-6 mRNA expression via NF-kB 
activation [257]. Based on this finding, we examined MAPKs activation and found higher 
phosphorylation of p38, but not ERK1/2 nor JNK, after torin2 treatment in our astrocyte 
cultures. Inhibition of p38 abolished the increase in mRNA IL-6 levels observed in torin2-
treated astrocytes, indicating that p38 activation is a crucial component in the cascade that 
triggers mRNA IL-6 expression upon PI3K-mTOR-AKT inhibition.  
 
As a following step, we went on to investigate the mechanisms controlling IL-6 secretion in 
astrocytes. Despite increasing IL-6 mRNA levels, blockade of the PI3K-mTOR-AKT 
pathway did not result in IL-6 protein secretion. Of interest, increased cytosolic Ca2+ caused 
as a result of “leaky” ryanodine receptors (RyR) facilitates IL-6 release [258]. Rapamycin, 
apart from blocking mTORC1, can also act by increasing the permeability of RyR [259]. 
Thus, we treated astrocytes with torin2 and rapamycin simultaneously, to increase IL-6 
mRNA and intracellular Ca2+ levels, respectively. Indeed, such approach lead to an 
astrocytic release of IL-6 in the culture media. Pre-treatment of astrocytes with the Ca2+ 
chelator BAPTA-AM prevented the IL-6 secretion mediated by the combined torin2 and 
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rapamycin treatment. Taken together, these findings demonstrate that IL-6 secretion from 
astrocytes requires both IL-6 mRNA expression and increased cytosolic Ca2+ levels.  
 
Next, we performed Ca2+ imaging and stimulated astrocytes with the RyR agonist 4-chloro-
m-cresol (4-cmc) to assess Ca2+ release from the ER. Interestingly, we observed that 
astrocytes treated with torin2 alone or together with rapamycin presented Ca2+ responses 
that were of smaller amplitude than in vehicle-treated astrocytes, suggesting a decrease in 
Ca2+ content from ER stores. Of note, the 4-cmc-induced Ca2+ responses were significantly 
lower in astrocytes treated with torin2 and rapamycin than if treated with torin2 alone. 
Figure 12 Diagram depicting IL-6 regulation in cultured astrocytes. A) In basal conditions the PI3K-mTOR-AKT 
pathway is active and prevents IL-6 expression in astrocytes. B) Inhibition of the PI3K-mTOR-AKT pathway by torin2 
results in p38 activation and NF-kB mediated IL-6 transcription. Torin2 also decreases the amount of Ca2+ stored in the 
ER, suggesting an increase is cytosolic Ca2+ levels. This increase in cytosolic is not sufficient to cause IL-6 secretion. 
C) When astrocytes are treated with torin2 and rapamycin, cytosolic Ca2+ levels increase sufficiently (due to RyR 
opening) to trigger IL-6 secretion. Figure modified from Study I. 
 32 
Thus, we hypothesized that torin2 treatment not only led to a depletion in Ca2+ stored in the 
ER, but presumably to an increase in cytosolic Ca2+ levels. Although this hypothetical 
increase in cytosolic Ca2+ might have not been sufficient to facilitate IL-6 secretion in 
astrocytes treated exclusively with torin2, in the presence of rapamycin, enhanced Ca2+ 
release from the ER into the cytosol could have been enough to trigger IL-6 secretion. 
Importantly, additional experiments are required to confirm our premise. 
 
IL-6 mRNA and protein expression has been previously reported in acute stages after SCI 
[260]. Particularly, at 12 hours after SCI, IL-6 mRNA expression seems to be mainly 
controlled by microglia/macrophages, astrocytes and neurons [261]. Despite this, the 
expression of IL-6 in later stages of SCI remains controversial. In agreement with the 
studies above, we found IL-6 expression acutely after injury, specifically at 6 hours post-
injury. Moreover, IL-6 was also detected at later stages, one to two weeks after SCI. 
Interestingly, we found that cells morphologically classified as neurons, astrocytes, immune 
cells and ependymal cells were able to synthesize IL-6 mRNA after SCI. We confirmed this 
observation by immunohistochemistry, which revealed that IL-6 co-localized with 
neuronal, microglial/macrophage and astrocytic cell markers after SCI.  
 
Additionally, we found that after SCI, the vast majority of astrocytes expressing IL-6 did 
not show any mTORC1 activity as indicated by p-S6 immunoreactivity, a downstream 
target of mTORC1 which is often used as a readout [127]. Notably, we found an increase in 
mTORC1 activity in astrocytes three weeks after injury, when IL-6 levels return to baseline 
and the glial scar is fully formed.  
 
Interestingly, several studies have suggested that IL-6 can act as a neuroprotective factor 
[124, 126]. Moreover, a study published earlier this year has reported that IL-6 can promote 
axonal regeneration and locomotor recovery after SCI in rats [262]. Therefore, stimulation 
of IL-6 production in the spinal cord in a time-controlled manner could be a promising 
strategy to improve recovery after SCI. Based on our in vitro and in vivo observations, we 
hypothesized that we could promote IL-6 secretion in the spinal cord of injured rats by 
blocking the PI3K-mTOR-AKT pathway during the sub-acute phase of SCI, when intrinsic 
levels of this cytokine are back to basal. Upon oral administration of torin2 and rapamycin, 
we found a transient reversal on mechanical hypersensitivity during the treatment window, 
despite a lack of improvement in locomotion recovery. Interestingly, several groups have 
reported that mTOR inhibition can have positive effects after SCI, including reduction of 
inflammation, tissue damage, glial scar formation, increased axonal regeneration as well as 
sensory and locomotor improvements [263-268]. On the other hand, other groups have 
reported positive effects upon mTOR activation after SCI [269, 270], indicating that the 
field is still quite controversial and that further investigations are required.  
 
Of note, we cannot rule out that the positive sensory effect observed in this study might 
have been mediated by other cell types, as the drugs were administered systemically. 
Furthermore, such effect could have been due to the regulation of additional mechanisms 
by mTOR, like autophagy or anti-inflammatory actions, which have been previously 
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reported [271-273]. Since some studies have reported a pro-nociceptive role of IL-6 in SCI 
[224, 228], it would have been interesting to assess whether IL-6 levels were elevated when 
mechanical hypersensitivity was attenuated. However, we lost such opportunity since we 
decided to continue the treatment regime to explore whether the beneficial effect could be 
maintained over time. Moreover, it could have been interesting to investigate if the 
treatment led to any changes in the glial scar or promoted axonal regeneration.  
 
In summary, in this study we have described that the inhibition of the PI3K-mTOR-AKT 
pathway is required for IL-6 production in astrocytes, an event that also relies on p38 and 
NF-kB activation. Moreover, we found that administration of torin2 and rapamycin in rats 
with SCI led to a transient improvement in mechanical hypersensitivity during the 
treatment period. Further work is needed to verify that IL-6 released by astrocytes 
contributed to the transient beneficial effect reported here.  
4.2 STUDY II: AN EX VIVO SPINAL CORD INJURY MODEL TO STUDY 
EPENDYMAL CELLS IN ADULT MOUSE 
Spinal cord injury (SCI) is a complex condition in which the interplay between cells and its 
surrounding environment influence disease progression. In this study, we aimed to develop 
a model of SCI that could serve as an intermediary step between in vitro and in vivo 
systems. We found organotypic slice cultures to be an attractive tool, since they retain the 
cytoarchitecture of the tissue of origin while allowing the study of cellular and molecular 
processes in an accessible way [274]. As traumatic SCI occurs mainly in adult individuals, 
we decided to use adult mouse spinal cord to set up our model. However, the use of adult 
tissue for preparation of organotypic slices can be quite challenging, due to a higher 
vulnerability to tissue damage upon slice sectioning and culturing conditions [275-277]. 
Taking this to our advantage, we postulated that slicing and culturing adult spinal cord 
could serve as an ex vivo model of SCI (Figure 13), which is characterized by an initial 
traumatic insult followed by secondary tissue damage.  
 
We originally intended to use this injury model to study astrocytes, and build-up on the 
findings presented in Study I. Thus, we decided to prepare spinal cord slices from 
transgenic mice which allow the visualization of astrocytes that express GFP under the 
control of the human Gfap promoter (hGfap-GFP) [233]. However, when imaging hGfap-
GFP cultured spinal cord slices over 7 days, we noted that the majority of astrocytes 
underwent cell death. On the contrary, we found that cells lining the central canal began to 
express GFP after 2-3 days in culture. By performing SCI in hGfap-GFP transgenic mice 
and staining for various ependymal markers, we corroborated that GFP expression was also 
taking place on the ependymal layer of SCI animals, thus ruling out that this phenomenon 
was an artefact of our ex vivo preparation. Moreover, we also performed immuno-
histochemistry in the spinal cord slices and found out that ependymal marker expression 
was maintained upon culturing. This prompted us to think that ependymal cells might be 
undergoing some kind of “activation” and that our ex vivo SCI model could then be well-
suited to study ependymal cell responses to injury. To confirm that, we assessed ependymal 
proliferation, migration and differentiation, which are characteristic events occurring after 
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traumatic SCI in different animal models [24, 108, 111]. Indeed, we found that ependymal 
cells could proliferate in culture, leading to an enlargement of the ependymal layer. 
However, while in the in vivo setting ependymal cells are usually arranged in 1-2 layers 
after SCI, in our ex vivo model they were arranged in multiple layers. This was possibly as 
a result of the culturing conditions, which lead to slice flattening over time. Despite this, we 
found very low variability in ependymal cell numbers across slides, indicating that 
proliferation can be quantified in a reproducible manner in this model.  
 
Using cultured spinal cord slices made from hFoxJ1-CreER::YFP mice, which label 
ependymal cells and their progeny in a specific, inducible and heritable manner [234], we 
found that ependymal cells gave rise to progeny that could migrate away from the 
ependymal layer (Figure 13). In animal models of SCI, ependymal progeny commonly 
migrates in a polarized manner towards the lesioned area [24, 111]. Here, we observed that 
ependymal progeny migrated radially in all directions, most likely as a result of the 
transectional damage inflicted on the slices upon sectioning. In agreement with the 
literature, we observed that some of the ependymal progeny expressed GFAP and Sox9, 
indicating a possible differentiation of the ependymal progeny towards the astrocytic 
lineage [24, 111]. While we did not assess whether these cells could give rise to 
oligodendrocytes, we found no evidence of ependymal-derived neurons in our model. This 
is an interesting finding since spinal cord ependymal cells can give rise to neurons when 
cultured in vitro, while this phenomenon does not seem to take place in vivo [118]. This 
indicates that the surrounding environment can significantly influence ependymal cells, 
which should be taken into account when studying injury-related cellular responses. 
 
Lastly, we performed Ca2+ imaging on ependymal cells, in order to verify that these cells 
were functionally active and viable in our SCI model. We used spinal cord slices cultured 
for 4-7 days, made from transgenic mice expressing the genetically encoded Ca2+ indicator 
GCaMP3 under the control of the mouse Gfap promoter (mGfap-Cre::GCaMP3). In 
contrast to the hGfap-GFP line, ependymal cells expressed mGfap in homeostatic 
conditions, as demonstrated by co-localization of ependymal markers with a tdTomato 
reporter driven by the mGfap promoter (mGfap-Cre::tdTomato). Since astrocytes also 
express mGfap, we selectively analyzed Ca2+ recordings from cells located in the 
Figure 13 A) Adult mouse spinal cord cultured slice. B) hFoxJ1-CreER::YFP labelled ependymal cells in the intact spinal 
cord C) hFoxJ1-CreER::YFP labelled ependymal cells proliferate and migrate out of the ependymal layer in adult mouse 
spinal cord slices kept in culture for 7 days. 
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ependymal layer and in proximal migrating cells, to minimize the inclusion of possible 
astrocytic responses.  Interestingly, we found that the majority of ependymal cells were able 
to respond to ATP stimulation, while a small proportion of ependymal cells exhibited 
spontaneous Ca2+ activity. While the functional implications of these Ca2+ responses were 
not investigated in this study, we can conclude that ependymal cells are functionally active 
and viable in our SCI model. Nevertheless, we believe that such Ca2+ transients could be 
involved in the proliferation, migration and differentiation of ependymal cells, since such 
cellular events can be regulated by Ca2+ [278]. Of note, ependymal cells have purinergic 
receptors and gap junctions [34, 279], indicating that Ca2+ could be an important messenger 
mediating ependymal-astrocyte communication. The fact that spontaneous Ca2+ activity 
was only observed in about 15% of the recorded cells could indicate that 1) these cells 
comprise a particular sub-population of ependymal cells 2) they may be ependymal-derived 
progeny on their way to astrocytic differentiation 3) they represent astrocytes, which are 
known to exhibit spontaneous Ca2+ activity [13]. Future studies using transgenic lines 
specifically allowing the study of Ca2+ responses in ependymal cells would be ideal to gain 
a better understanding of the role of Ca2+ signalling in the ependymal cell response to injury 
and to corroborate our observations. 
 
The model described here can serve different potential applications. For instance, it can 
facilitate the study of injury-related cellular processes with live imaging techniques in cells 
that are normally found at a considerable depth in vivo. In addition, it could also serve as a 
platform to reprogram ependymal cells into suitable progeny cell types in an injury setting, 
or to modulate the ependymal response to injury by testing different external effectors in a 
high-throughput manner.   
 
Taken together, in this study we have demonstrated that cultured spinal cord slices are an 
excellent model of ex vivo SCI for the study of ependymal cells. We have shown that, in 
this model, ependymal cells recapitulate the main events that occur after injury in the in 
vivo setting, including proliferation, migration and differentiation. Furthermore, we suggest 
that ependymal cells can exhibit spontaneous Ca2+ activity and respond to ATP stimulation. 
Moreover, we propose the use of hGfap-GFP transgenic mice as a practical tool to visualize 
and track ependymal cells after injury in vivo and ex vivo. To conclude, we believe that our 
model provides an attractive platform to study and modulate ependymal cell responses that 
could complement in vivo studies and possibly contribute to the development of novel 
treatment avenues for SCI.  
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4.3 STUDY III: CENTRAL NERVOUS SYSTEM AUTOIMMUNITY IN 
RHEUMATOID ARTHRITIS: ANTI-CITRULLINATED PEPTIDE ANTIBODIES 
ACTIVATE HUMAN ASTROGLIAL CELLS AND INDUCE PAIN BEHAVIOUR 
IN MICE 
Pain experienced by individuals with RA have been often attributed to inflammatory 
processes in the affected joints. However, there is current evidence indicating that central 
sensitization can also contribute to pain in RA [187]. Here, we went on to study whether 
anti-citrullinated peptide antibodies (ACPA), which have pro-nociceptive effects when 
injected systemically [163], could be found in the CSF of RA patients and be involved in 
centrally-mediated pain signal transmission by acting on resident cells of the CNS.  
 
In this study, we describe, for the first time, the presence of ACPA in the CSF of RA 
individuals with high levels of ACPA in serum. ACPA was undetectable in CSF samples 
from patients with multiple sclerosis or non-inflammatory disease, which served as 
negative controls (Figure 14A). To ascertain the potential origin of the ACPA found in the 
CSF, we carried out several experiments. Firstly, we assessed the pattern of ACPA 
specificity towards common citrullinated epitopes and found that ACPA from serum and 
CSF samples had strong affinity to the same antigens. Secondly, we compared the 
serum/CSF ratios of ACPA and systemically produced anti-influenza antibodies, revealing 
no differences among the two. Taken together, the findings above point to a systemic rather 
than intrathecal production of ACPA, which most likely enter the CSF by redistribution 
from the periphery. Nevertheless, we cannot exclude the possibility that these antibodies 
might have been locally produced within the CNS. 
 
Under pathological conditions, antibodies can penetrate blood-CNS-barriers as a result of 
local or systemic inflammation [280]. Interestingly, RA patients present elevated levels of 
IL-1ß in the CSF [216], and this particular cytokine can lead to alterations in blood-brain-
barrier (BBB) permeability in several experimental studies [281-284]. Intriguingly, none of 
the RA patients examined had altered blood-CNS-barriers, as indicated by normal albumin 
indexes. Although it may seem controversial, antibody redistribution from the blood to the 
CSF/CNS over intact barriers has been previously reported, both by active transport or 
through the circumventricular organs, which lack a fully functional BBB [285, 286].  
 
In this study, we also report that mice intrathecally (i.t.) injected with ACPA (30 µg) 
showed cold and mechanical hypersensitivity as compared to animals i.t. injected with 
ACPA-negative IgG from RA patients (referred to as flow through, FT, 30 µg), healthy IgG 
(30 µg) or PBS (Figure 14B, FT not shown). This is in contrast to mice that were 
intravenously (i.v.) injected with ACPA (125 µg to 4 mg), which also display signs of heat 
hypersensitivity [163]. However, while there are apparent differences in some aspects of 
the ACPA-induced pain observed in i.t. and i.v. injected animals, we cannot rule out that 
the pro-nociceptive effects described here are partially due to a redistribution of ACPA 
from the CSF to the periphery. Further studies are warranted to determine if this is the case. 
One possibility could be to inject ACPA i.v. at the dose used in this study (30 µg), and see 
whether hypersensitivity is induced or not. Alternatively, it would also be interesting to 
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investigate whether pro-nociceptive effects 
are observed upon injection of ACPA 
directly into the CNS parenchyma. 
Certainly, it is tempting to speculate that 
ACPA found in the CSF (and potentially in 
the CNS) could be responsible for the 
residual pain that only a subset of ACPA-
positive RA patients experience, despite 
taking appropriate medication for their 
condition [182].   
 
Next, we decided to investigate whether 
ACPA could potentially interact with 
resident cells of the CNS. We focused on 
potential effects ACPA could exert on 
astrocytes, as they form a functional barrier 
that separates the CNS parenchyma from the 
vasculature and the meninges [21]. Most 
importantly, there is increasing evidence 
showing that astrocytes play an important 
role in the induction and maintenance of 
chronic pain [154, 188, 203, 217, 287]. 
Therefore, we reasoned that, if ACPA were 
to enter the CNS, they could initially act on 
astrocytes to drive central pain processes. 
We found that co-stimulation of cultured 
human fetal astrocytes with ACPA and IL-
1ß, factors that are present in the CSF of RA 
patients, led to an increase in IL-6 mRNA 
levels and IL-1ß-induced IL-6 release, as 
compared to astrocytes co-stimulated with 
healthy IgG and IL-1ß. Stimulation with 
ACPA alone failed to induce IL-6 mRNA 
transcription and IL-6 release from 
astrocytes. This observation prompted us to 
think that ACPA might be forming immune 
complexes which could act on astrocytes by 
binding FcγRs. Of interest, FcγRI has been 
linked to pro-nociceptive signalling [167, 
168]. Notably, we found that astrocytes in 
culture expressed FcγRI and that incubation 
of astrocytes with an FcγRI inhibitor 
abolished the enhanced IL-6 release caused 
by ACPA and IL-1ß co-stimulation (Figure 
Figure 14 A) ACPA were detected in the CSF of 
rheumatoid arthritis (RA) patients in contrast to 
individuals with multiple sclerosis (MS) and non-
inflammatory disease (OND). B) Mice i.t. injected with 
ACPA show mechanical hypersensitivity as compared to 
mice i.t. injected with healthy IgG or PBS. C) Co-
stimulation of human fetal astrocytes with IL-1ß and 
ACPA significantly increases IL-6 release as compared 
to other conditions. This effect is abolished in the 
presence of an FcγRI inhibitor. C, insert) Human fetal 
astrocytes express FcγRI. Figure modified from Study 
III.   
 38 
14C). In the future, we aim to determine whether astrocytes express citrullinated epitopes 
that could be involved in immune complex formation or serve as antigens for ACPA. 
Interesting candidates include vimentin and GFAP, proteins that are expressed and 
upregulated upon astrocyte activation. Particularly, citrullinated vimentin is an important 
factor for immune complex formation in the synovial fluid of ACPA-positive RA patients 
[288], and both vimentin and GFAP levels are elevated in synovial fluid and serum of 
individuals with RA [289]. Of note, citrullinated GFAP has been reported in the brain of 
patients with multiple sclerosis, and it is thought to play a role in the pathophysiology of 
the disease [290].  
 
To conclude, our findings favour the idea that ACPA may potentially reach the CNS of RA 
patients, act on glial cells and activate mechanisms that could promote central 
sensitization. Future work should aim at elucidating whether ACPA can certainly be 
detected in the CNS of RA patients. Moreover, it could also be interesting to investigate 
whether ACPA could mediate central effects by interacting with other cell types in the 
CNS/CSF.  
4.4 STUDY IV: EXPLORING THE TRANSCRIPTOME OF RESIDENT SPINAL 
MICROGLIA AFTER COLLAGEN ANTIBODY-INDUCED ARTHRITIS 
The contribution of male and female microglia to experimental chronic pain states is 
currently under debate. While some studies have provided evidence for an exclusive role of 
male microglia, others have reported that female microglia might also be involved [230, 
231, 291].  
 
In this study, we went on to study possible differences in male and female lumbar dorsal 
horn spinal microglia in the context of arthritis-induced pain. We used the CAIA animal 
model, which is characterized by transient joint inflammation and persistent mechanical 
hypersensitivity [154]. These animals display a concomitant increase in male and female 
microglial IBA-1 reactivity in the dorsal horns of the lumbar spinal cord (where hind limb 
nociceptive processing occurs), suggesting that microglia could be involved in the 
maintenance of arthritis-induced pain in both sexes (Figure 15A). To test if this was the 
case, we injected minocycline (often described as a “microglial inhibitor”) intrathecally into 
male and female mice during the late phase of the CAIA model (Figure 15B,C), when joint 
inflammation has resolved but mechanical hypersensitivity and microglial activation are 
still present. In agreement with data from neuropathic pain models, we found that 
minocycline was only able to revert CAIA-induced pain to control levels in male mice 
[230, 232]. Although these findings point to a sexually dimorphic role of microglia in the 
maintenance of persistent pain states, it is important to note that minocycline is not a 
selective microglial inhibitor [292]. Hence, we advise for a prudent interpretation of these 
results and those in the existing literature with regards to the cell type mediating such 
effects.  
 
In light of the findings described above, we decided to take a global approach to explore 
microglial transcriptional sex-differences in relation to CAIA-induced persistent pain. 
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Initially, we investigated whether macrophages could infiltrate into the lumbar spinal cord 
after CAIA induction, as this would require the use of additional markers to discriminate 
them from resident microglia. Since we found no signs of macrophage infiltration at the 
different time points examined after CAIA induction, we decided to sort resident lumbar 
dorsal horn microglia by FACS using CD45 and CD11b as markers. We found no 
differences in relative microglial numbers between saline and late phase CAIA conditions, 
however, when comparing male and female microglia, we observed a lower proportion of 
spinal microglia in female mice. In line with our findings, sex differences in microglial cell 
numbers have also been reported in brain areas such as the hippocampus or the amygdala 
[54].  
 
Upon sequencing, we found 11,567 genes expressed in our lumbar dorsal horn microglia 
samples. Of note, there was an 85% overlap between our dataset and other RNA-seq studies 
performed on microglia isolated from the brain or spinal cord [170, 293-296]. We 
compared microglial transcriptomes by principal-component analysis (PCA) and found that 
male and female samples were well separated into two distinguishable groups (Figure 16A). 
We detected 21 differentially expressed genes among both sexes, 5 of which were X or Y 
linked genes. When re-running the PCA analysis without the differentially expressed sex-
linked genes, male and female samples were no longer separated into groups, indicating 
that microglial transcriptional sex differences are limited and mostly accounted for by sex-
linked genes. Despite this, we went on to explore putative interactions between the top 46 
male and female dysregulated genes (unadjusted p-value <0.001) and found that members 
of the heat shock protein (Hsp) family comprised most of the gene network generated 
(Figure 16B). Hsp were mostly upregulated in male microglia and were highly 
interconnected. Notably, sex differences in Hsp have been reported in the literature [297-
299]. Moreover, Hsp have been associated with microglia activation [206, 300] and pain 
processing [204, 205], making them an attractive target for future studies and for 
independent validation of our RNA-seq results.    
 
 
 
Figure 15 A) Male and female mice injected with CII antibodies (CAIA model) show microglia reactivity as compared 
to saline injected mice. B,C) Minocycline injected intrathecally reverts CAIA-induced mechanical hypersensitivity in 
males but not females. Figure adapted from Study IV.  
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Intriguingly, we did not identify any convincing transcriptional differences between the 
saline and late phase CAIA groups, despite being well-powered to detect 1.5-2.0 fold 
changes in gene expression in the top 3,000 expressed genes. This observation may indicate 
that 1) transcriptional changes during the late phase of the CAIA model are either subtle 
and/or highly localized, and hence difficult to detect using bulk RNA-seq 2) transcriptional 
changes after CAIA induction are transient and short-lasting 3) the microglia separation 
protocol might have induced similar activation in microglia from saline and CAIA groups, 
masking any transcriptional differences that may be present in vivo. We believe this last 
point to be unlikely, as other RNA-seq studies which have used similar microglial isolation 
protocols still identify transcriptional differences between conditions [301-303]. The fact 
that no transcriptional changes were detected between the saline and CAIA groups suggests 
that late phase CAIA microglial activation and the potential involvement of microglia in 
CAIA-induced pain could be mediated by other factors, like changes in protein expression 
or epigenetic modifications.  
 
Taken together, our findings provide evidence for subtle but significant sex differences in 
spinal microglia isolated from lumbar dorsal horns. The extent to which such differences 
could bring about the dimorphic effect of minocycline in CAIA-induced pain remains to be 
elucidated. Although we observed signs of microglia activation in the late phase of CAIA, 
no transcriptional changes were detected when compared to controls. Therefore, it seems 
likely that changes in gene expression were subtle, highly localized or short-lasting. 
Complementary behavioral studies using tools that target specific microglial pathways 
could be a suitable strategy to get a clearer picture as to the role of male and female 
microglia in CAIA-induced pain. 
 
  
Figure 16 A) Principal component analysis comparing male and female microglia in mice i.v. injected with saline or 
subjected to CAIA. B) Gene network showing differentially expressed genes in male vs female microglia using different 
p-values as a cut-off. Circles: unadjusted p<0.001; rectangles: adjusted p<0.05; octagons: adjusted p<0.1. Blue genes are 
also differentially expressed in male vs. female sensory neurons. Yellow genes belong to the family of heat shock 
proteins. Figure modified from Study IV. 
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5 CONCLUDING REMARKS 
In this thesis, we have focused on deepening our understanding of glial pathophysiological 
events in relation to spinal cord injury, rheumatoid arthritis and pain-related processes. A 
running theme across our work has been to make our studies as translational as possible, 
either by incorporating animal models and patient material or by developing a model that 
could serve as a bridge between in vitro and in vivo platforms to study glial cell responses. 
When possible, we have also tried to go from single molecules to cellular responses all the 
way to finding behavioral outcomes.  
 
Importantly, the role that glial cells play on pathological process is by no means static. Glia 
are very dynamic and can respond differently according to the environment. It is therefore 
that the study of glial cells at different stages of disease becomes critical to understand how 
to harness their full potential while avoiding any associated detrimental consequences. 
Indeed, the modulation of glial cells as a strategy to improve the outcome of SCI is 
capturing the attention of the scientific community. In Study I, we went from deciphering 
molecular pathways in cultured astrocytes to applying such concepts in vivo to try and 
modulate astrocytes after SCI. Moreover, in Study II, we have described an attractive 
platform to modulate ependymal cell responses in an injury setting, which could aid in the 
development of novel treatment avenues for SCI.       
 
It is an intriguing thought that difficulties in developing new pain therapeutics may in part 
be due to an overseen role of glia. Hence, it is critical to explore the role of these cells in 
pain transmission to determine the feasibility of targeting astrocytes and/or microglia in 
conditions of chronic pain. In Study III, we have provided an interesting hypothesis as to 
how central sensitization could be driven in RA, which may depend on the interaction of 
autoantibodies and astrocytes. In Study IV we decided to study the role of transcriptional 
changes in microglia in arthritis-induced persistent pain paying particular attention to sex-
differences. While transcriptional changes did not drive persistent pain in at the time point 
studied, we found some differences in male and female microglia. Further investigations 
are warranted to clarify whether the sex-related role of glia is restricted to selected 
mechanisms, pain modalities or animal models, and how these observations could be 
relevant to clinical pain. 
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